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A B S T R A C T
Background
Nonsteroidal anti-inflammatory drugs (NSAIDs) provide effective analgesia during the post-operative period but can cause acute kidney
injury (AKI) when used peri-operatively (at or around the time of surgery). This is an update of a Cochrane review published in 2007.
Objectives
This review looked at the effect of NSAIDs used in the peri-operative period on post-operative kidney function in patients with normal
kidney function.
Search methods
We searched Cochrane Kidney and Transplant’s Specialised Register to 4 January 2018 through contact with the Information Specialist
using search terms relevant to this review. Studies in the Specialised Register are identified through searches of CENTRAL, MEDLINE,
and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.
Selection criteria
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of
alternate medical records, date of birth or other predictable methods) looking at the use of NSAIDs versus placebo for the treatment
of post-operative pain in patients with normal kidney function were included.
Data collection and analysis
Data extraction was carried out independently by two authors as was assessment of risk of bias. Disagreements were resolved by a third
author. Dichotomous outcomes are reported as relative risk (RR) and continuous outcomes as mean difference (MD) together with
their 95% confidence intervals (CI). Meta-analyses were used to assess the outcomes of AKI, change in serum creatinine (SCr), urine
output, renal replacement therapy (RRT), death (all causes) and length of hospital stay.
1Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We identified 26 studies (8835 participants). Risk of bias was high in 17, unclear in 6and low in three studies. There was high risk of
attrition bias in six studies.
Only two studies measured AKI. The use of NSAIDs had uncertain effects on the incidence of AKI compared to placebo (7066
participants: RR 1.79, 95%CI 0.40 to 7.96; I2 = 59%; very low certainty evidence). One study was stopped early by the data monitoring
committee due to increased rates of AKI in the NSAID group. Moreover, both of these studies were examining NSAIDs for indications
other than analgesia and therefore utilised relatively low doses.
Compared to placebo, NSAIDs may slightly increase serum SCr (15 studies, 794 participants: MD 3.23 µmol/L, 95% CI -0.80 to
7.26; I2 = 63%; low certainty evidence). Studies displayed moderate to high heterogeneity and had multiple exclusion criteria including
age and so were not representative of patients undergoing surgery. Three of these studies excluded patients if their creatinine rose post-
operatively.
NSAIDs may make little or no difference to post-operative urine output compared to placebo (6 studies, 149 participants: SMD -
0.02, 95% CI -0.31 to 0.27). No reliable conclusions could be drawn from these studies due to the differing units of measurements
and measurement time points.
It is uncertain whether NSAIDs leads to the need for RRT because the certainty of this evidence is very low (2 studies, 7056 participants:
RR 1.57, 95% CI 0.49 to 5.07; I2 = 26%); there were few events and the results were inconsistent.
It is uncertain whether NSAIDs lead to more deaths (2 studies, 312 participants: RR 1.44, 95% CI 0.19 to 11.12; I2 = 38%) or
increased the length of hospital stay (3 studies, 410 participants: MD 0.12 days, 95% CI -0.48 to 0.72; I2 = 24%).
Authors’ conclusions
Overall NSAIDs had uncertain effects on the risk of post-operative AKI, may slightly increase post-operative SCr, and it is uncertain
whether NSAIDs lead to the need for RRT, death or increases the length of hospital stay. The available data therefore does not confirm
the safety of NSAIDs in patients undergoing surgery. Further larger studies using the Kidney Disease Improving Global Outcomes
definition for AKI including patients with co-morbidities are required to confirm these findings. .
P L A I N L A N G U A G E S U M M A R Y
Effect of nonsteroidal anti-inflammatory medicines on kidney function in patients with normal kidney function undergoing
surgery
What is the issue?
Nonsteroidal anti-inflammatory drugs (NSAIDs) offer effective pain relief following surgery. Acute kidney injury (AKI) is the rapid
loss of kidney function. It is associated with high death rate. NSAIDs can lead to AKI in up to 5% of patients using them. This is
increased when there are other stresses placed on the kidney such as surgery. It is therefore important to establish whether these drugs
are safe to use as pain relief in patients undergoing surgery. The aim of the review was to examine whether NSAIDs lead to increased
rates of AKI in patients with normal kidney function undergoing surgery. We also aimed to examine whether NSAIDs were associated
with higher death rates, increased length of hospital stay and need for dialysis.
What did we do?
We updated a previous review searching the Cochrane Kidney and Transplant Specialised Register until 4 January 2018 for randomised
controlled trials (RCTs) comparing NSAIDs with placebo in patients with normal kidney function undergoing surgery.
What did we find?
We identified 26 studies studying 8835 participants. Risk of bias was high in 17, unclear in six studies and low in three studies. The use
NSAIDs had uncertain effects on the incidence of AKI compared to placebo. Quality of evidence was very low due to inconsistencies
between the two studies. One study was stopped early by the data monitoring committee due to increased rates of AKI in the NSAID
group and both of these studies examined much lower doses of NSAIDs than would usually be used for pain relief. NSAIDsmay slightly
increase serum creatinine (a marker of kidney function which rises in kidney failure) compared with placebo. Quality of evidence
was low. These studies only included fit, healthy patients. No reliable conclusions could be drawn from the studies examining urine
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output due to the different methods of measuring this. It is uncertain whether the use of NSAIDs leads to an increased need for renal
replacement therapy (dialysis), more deaths, or increased length of hospital stay.
Conclusions
NSAIDs have uncertain effects on the rates of AKI when used in patients with normal kidney function following surgery. It is uncertain
whether NSAIDs increase the need for dialysis. The available data therefore does not confirm the safety of NSAIDs in patients
undergoing surgery. Further studies including patients with other health problems are required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NSAIDs versus placebo or no treatment in the peri-operative period
Patient or population: adults with normal kidney funct ion undergoing surgery
Settings: hospitals, mainly high-income countries (North America or Western Europe)
Intervention: administrat ion of NSAIDs in the peri-operat ive period
Comparison: placebo or no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Intervention (NSAID)
AKI within 30 days of
surgery
12 per 100 13 per 100
(12 to 14)
RR 1.79 (0.40 to 7.96) 7066 (2) ⊕©©©
very low1
NAFARM 2011 was
stopped by study mon-
itoring committee be-
cause of increased risk
of AKI. Both studies
used NSAID doses that
were much lower than
would be used for anal-
gesia in usual care.
The results raise seri-
ous concerns about the
safety of post-operat ive
analgesia with NSAIDs
in unselected pat ients
SCr increase within 30
days of surgery
The mean dif ference in
SCr in control group
was decreased by -2.60
µmol/ L
The mean dif ference in
SCr in the intervent ion
group was increased by
1.52 µmol/ L (-7.4 to 10.
2)
Dif ference in post-oper-
at ive SCr increased by
3.23 µmol/ L (-0.8 to 7.
26)
794 (15) ⊕⊕©©
low2
Heterogeneity was not
explained by pre-spec-
if ied ef fect modif iers
(Table 1, Figure 1)
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RRT within 30 days of
surgery
2 per 1000 5 per 1000
(2 to 11)
RR 1.57 (0.49 to 5.07) 7056 (2) ⊕©©©
very low3
--
Death (all causes) 2 per 100 3 per 100
(0 to 6)
RR 1.44 (0.19 to 11.12) 312 (2) ⊕©©©
very low3
--
Length of hospital stay The mean length of
hospital stay in control
group was 10.0 days
The mean length of hos-
pital stay in the inter-
vent ion group was 10.6
days (range 5.3 to 18.
33)
MD 0.12 (-0.48 to 0.72) 410 (3) ⊕©©©
very low3
--
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk Ratio; MD: mean dif ference; AKI: acute kidney injury; SCr: serum creat inine; RRT: renal replacement therapy
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
The assumed risk is the median or mean across the control groups for each intervent ion
1 1 downgrade for study lim itat ions, one for imprecision, and one for heterogeneity (Appendix 3).
2 We downgraded the certainty of evidence to low because of inconsistency and indirectness (Appendix 3).
3 We downgraded the certainty of evidence to very low because of risk of bias, imprecision, inconsistency and indirectness
(Appendix 3).
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Figure 1. Meta-regression of change in post-operative serum creatinine (Analysis 2.1) by type of surgery,
duration of NSAID use, and exclusion by age. Results are Beta with 95% CI. A positive value for Beta indicates
that a variable is associated with increased effect size.
B A C K G R O U N D
Description of the condition
There is increasing evidence that acute kidney injury (AKI) is as-
sociated with both short- and long-term adverse consequences.
These include increased length of hospital stay, death and future
development of chronic kidney disease (CKD) even with small
transient rises in serum creatinine (SCr) (Bucaloiu 2012; Chertow
2005; Coca 2012; Lassnigg 2004). Surgery is a leading cause of
AKI in hospitalised patients (Carmichael 2003). There was previ-
ously significant variation indefiningAKI.These included changes
in SCr, urine output and creatinine clearance (CrCl). The Kid-
ney Disease Improving Global Outcomes (KDIGO) definition
has been universally accepted since 2012 KDIGO 2012.
Effective management of post-operative pain is extremely impor-
tant. It facilitates earlymobilisation thereby reducing hospital costs
through shortened duration of hospital in-patient stay, reduces
pulmonary and cardiovascular complications and risk of deep vein
thrombosis. In addition, it impacts on quality of patient care by
relieving suffering and distress and improving satisfaction. The
major aim of post-operative pain management is providing ade-
quate pain relief using theminimal possible dose therebyminimis-
ing adverse effects. Clinical guidelines for managing perioperative
pain by the American Pain Society, the American Society of Re-
gional Anesthesia and PainMedicine, and the American Society of
Anesthesiologists’ Committee on Regional Anesthesia, Executive
Committee, and Administrative Council were published in 2016
(Chou 2016). They recommend a multimodal approach to post-
operative pain including the use of both nonselective nonsteroidal
anti-inflammatory drugs; (NSAIDs) as well as selective NSAIDs
(Cox-2 inhibitors). NSAIDs can affect the kidneys in a number of
ways. This includes haemodynamically mediated AKI, electrolyte
and acid-base disorders and acute interstitial nephritis. These ad-
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verse effects are thought to occur in 1% to 5% of all patients using
NSAIDs (Whelton 1999).
Description of the intervention
NSAIDs inhibit prostaglandin synthesis by inhibiting cyclooxyge-
nase-1 (Cox-1) and cyclooxygenase -2 (Cox-2). Cox-1 is expressed
in most tissues regulating normal cellular processes such as gastric
cytoprotection, vascular homeostasis, platelet aggregation and kid-
ney function. Cox-2 is expressed in brain, kidney and bone. Most
traditionalNSAIDs are non-selective inhibitors of bothCox-1 and
Cox-2. Selective Cox-2 inhibitors include celecoxib, rofecoxib and
valdecoxib.
Cyclooxygenases are produced at multiple sites within the kid-
ney including glomerular and vascular endothelium, medullary
and cortical collecting tubules and medullary interstitial cells.
Cox-1 is expressed in most tissues and Cox-2 is expressed at low
levels increasing with stimulation such as inflammation. Renal
prostaglandins are primarily vasodilators in the kidneys. Under
normal circumstances, renal prostaglandins do not contribute to
regulation of kidney perfusion but in the setting of hypotension
and reduced kidney perfusion fromvasoconstrictionprostaglandin
synthesis is increased to maintain kidney perfusion and mini-
mize ischaemia. Other kidney effects of prostaglandins include in-
creased renin secretion, antagonism of anti-diuretic hormone ef-
fects and increased sodium excretion.
How the intervention might work
The use of both non-selective and selective NSAIDs for post-op-
erative pain has been evaluated in a number of Cochrane reviews.
A single dose of ibuprofen lead to at least 50% pain relief in ap-
proximately half of patients with moderate to severe post-opera-
tive pain. Adverse effects were similar to placebo (Derry 2009).
Aspirin was found to confer a 50% or greater reduction in pain in
39% of those with moderate to severe pain, compared with 15%
of those in the placebo group. Adverse events were similar for those
taking a lower dose aspirin (600 mg or 650 mg). However, higher
dose aspirin (900 mg to 1000 mg) experienced adverse events at
more than twice the rate of patients receiving placebo (26% ver-
sus 12%) (Derry 2012a). The use of a single dose of the Cox-2
inhibitor celecoxib in the treatment of acute post-operative pain
showed that 33% of patients receiving celecoxib 200mg, and 44%
receiving 400 mg, experienced at least 50% pain relief, compared
with between 1% and 11% of patients receiving placebo. Adverse
events were similar in the celecoxib and placebo groups (Derry
2012b).
Furthermore, there is evidence supporting the efficacy of NSAIDs
for post-operative pain with studies demonstrating opioid sparing
effects (McDaid 2010).
NSAIDs have the potential to adversely affect kidney function in
the peri-operative setting. Pre-renal insults such as hypovolaemia
or hypotension peri-operatively cause NSAID-induced inhibition
of prostaglandin mediated afferent arteriolar dilatation leading to
reduced glomerular perfusion. The risk of AKI with NSAIDs has
led the Medicines and Healthcare Products Regulatory Agency to
issue drug safety advice recommending thatNSAIDs be avoided in
patients with hypovolaemia (MHRA 2009). Other adverse events
associated with NSAIDs include gastrointestinal bleeding and car-
diovascular events. These were not examined in this review.
Why it is important to do this review
This is an update of a Cochrane review last published in 2007 (Lee
2007). This review showed that NSAIDs caused a clinically unim-
portant transient reduction in kidney function in the early post-
operative period in patients with normal kidney function. Since
its publication, a universal definition for AKI has been developed
allowing a better understanding of its epidemiology and clinical
significance (KDIGO2012). Since the advent of the KDIGOdef-
inition for AKI, there is increasing evidence of the adverse clinical
and economic consequences of AKI. In addition, National Insti-
tute for Clinical Excellence (NICE) AKI guidance recommends
the avoidance of NSAIDs in the post-operative period (Ftouh
2013).
It is therefore important to re-assess the renal safety of NSAIDs in
the peri-operative period.
O B J E C T I V E S
This review looked at the effect of NSAIDs used in the peri-
operative period on post-operative kidney function in patients
with normal kidney function.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs
in which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) looking at the use of NSAIDs versus placebo in the
post-operative phase in adults with normal kidney function were
included.
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Types of participants
People of at least 18 years of age undergoing surgical procedures
who were treated with NSAIDs or Cox-2 inhibitors with normal
kidney function were included. Normal kidney function was de-
fined as estimated glomerular filtration rate (eGFR) > 60mL/min/
1.73 mm2 without other evidence of kidney disease (proteinuria,
haematuria, genetic kidney disease or structural kidney abnormal-
ities).
Types of interventions
All interventions comparing NSAID treatments including Cox-
2 inhibitors versus placebo were considered. Variable doses, all
routes of administration and variable indications for NSAID use
were considered.
Types of outcome measures
The primary endpoint was AKI. Studies measuring SCr and urine
output in the post-operative phase were also considered. The sec-
ondary outcomes of length of hospital stay, death and requirement
of renal replacement therapy (RRT) were documented when avail-
able.
Primary outcomes
The primary outcome was AKI as defined by KDIGO which is
based on SCr or urine output (KDIGO 2012). Change in SCr
and urine output were also considered using the highest post-
operative creatinine or lowest post-operative urine volume. These
were analysed separately.
Secondary outcomes
1. Need for RRT
2. Death (all causes)
3. Length of hospital stay
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 4 January 2018 through contact with the Infor-
mation Specialist using search terms relevant to this review. The
Cochrane Kidney and Transplant Specialised Register contains
studies identified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies relevant to the review.The titles and abstractswere
screened independently by two authors, who discarded studies
that were not applicable, however studies and reviews that might
include relevant data or information on studies were retained ini-
tially. Two authors independently assessed retrieved abstracts and,
if necessary the full text, of these studies to determine which stud-
ies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors us-
ing standard data extraction forms. Studies reported in non-En-
glish language journals were translated before assessment. Where
more than one publication of one study existed, reports were
grouped together and the publication with themost complete data
were used in the analyses. Data extracted included study design,
inclusion and exclusion criteria, patient numbers and characteris-
tics and treatment regimen. For outcomes of interest (AKI, serum,
creatinine, urine output, death, need for RRT and length of hos-
pital stay), the raw data were extracted using mean, median and
standard deviations for continuous outcomes, and event rate for
dichotomous outcomes. Where data were collected at more than
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one time-point, these were all extracted. Peak SCr and lowest urine
volume were used for the analyses.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
In each domain, studies were labelled as low, high or unclear risk
of bias with consideration given to the presence or absence of suf-
ficient information to make a determination. Reasons for assess-
ment were documented (See Characteristics of included studies),
and a risk of bias summary is presented.
Measures of treatment effect
For the dichotomous outcomes (presence of AKI, need for RRT
and death), results were expressed as risk ratio (RR) with 95%
confidence intervals (CI). Continuous scales of measurement such
as mean difference (MD) and 95% CI was used to assess the ef-
fects of treatment for change in SCr and length of hospital stay.
SCr was converted to standardised units (µmol/L) and peak post-
operative creatinine was used when more than one post-operative
creatinine was reported. Mean change in SCr was not given in
studies and so the correlation coefficient between pre and post-
operative measures were not known. We therefore assumed a cor-
relation coefficient of 0.50 (Follmann 1992). A sensitivity analysis
was carried out assuming zero correlation. The standard deviation
between pre and post-operative measures for each treatment group
was estimated using a method outlined in the Cochrane Collabo-
ration Handbook. When the median and interquartile range were
reported, we assumed that the mean was equivalent to the median
and estimated the standard deviation to be the interquartile range/
1.35 (O’Rourke 2002). Standardised mean difference (SMD) was
used for urine output as different scales were used. Lowest post-
operative urine output was used when more than one time point
was measured.
In studies comparingmultiple differentNSAIDs or varying dosing
regimens, the dose or dugwith the greatest adverse effect on kidney
function was included in the analysis.
Unit of analysis issues
Studies with non-standard designs, such as cross-over studies and
cluster-randomised studies were not included in this review.
Dealing with missing data
We did not contact any authors as the required information was
present in the studies. Evaluation of important numerical data
such as screened, randomised patients as well as intention-to-treat,
as-treated and per-protocol population was carefully performed.
Attrition rates, for example drop-outs, losses to follow-up and
withdrawals were investigated. Issues of missing data and imputa-
tionmethods (for example, last-observation-carried-forward) were
critically appraised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
Funnel plots were used to assess for the potential existence of small
study bias (Higgins 2011).
Data synthesis
Data were pooled using the random-effects model but the fixed-
effect model was also be used to ensure robustness of the model
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Meta-regression was carried out to investigate possible explana-
tions for heterogeneity of effects, including type of surgery (cardiac
versus other), duration of NSAID therapy (>24h versus <24h) and
whether age was an exclusion criterion (no versus yes) as potential
explanatory variables. Meta-regression used standard weighted (by
standard error of estimate) linear regression in IBM SPSS Statistics
22.
Sensitivity analysis
We planned to perform sensitivity analyses if there were sufficient
studies identified, in order to explore the influence of the following
factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
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• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
We were only able to investigate the influence of risk of bias on
effect size due to the number of studies identified. The analysis
was repeated excluding studies with high risk of bias, attrition bias
or high risk of bias or attrition bias.
’Summary of findings’ tables
We presented the main results of the review in ’Summary of find-
ings’ tables. These tables present key information concerning the
quality of the evidence, the magnitude of the effects of the in-
terventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of
a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the true quan-
tity of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological qual-
ity), directness of evidence, heterogeneity, precision of effect es-
timates and risk of publication bias (Schünemann 2011b). We
presented the following outcomes in Summary of findings for the
main comparison.
• AKI within 30 days of surgery
• Mean difference in SCr increase in µmol/L within 30 days
of surgery
• RRT within 30 days of surgery
• Death (all causes)
• Length of hospital stay (days)
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies
Results of the search
In total 659 records were identified through database searches, and
two records were added through other means. Forty-five records
were duplicates and were excluded. The titles and abstracts of the
remaining616 recordswere reviewedby two independent assessors
and 52 records were deemed eligible for full text review. Nineteen
records (21 studies) were excluded; details about the reason for
exclusion can be found in the table Characteristics of excluded
studies. The remaining 31 records (26 studies) were included (see
Figure 2).
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Figure 2. Study flow diagram.
Included studies
Twenty-six studies (8943 patients) met our inclusion criteria. A
detailed overview of all the included studies can be found in the
Characteristics of included studies table. The studies were con-
ducted between 1992 and 2017 and included adults with pre-
served kidney function prior to surgery. Of these, 19 (8107 par-
ticipants) could be meta-analysed.
Six studies (Chow 2001;Castiglione 1997;Nuutinen 1991; Parker
1994; Ready 1994; Rao 2000) included in the previous version of
this review (Lee 2007), were not included in our review. One study
enrolled patients who underwent a nephrectomy (Chow 2001);
one study used NSAID in both groups (Castiglione 1997); and
four studies were excluded due to the absence of concise post-op-
erative kidney outcomes in these studies (Nuutinen 1991; Parker
1994; Ready 1994; Rao 2000) - in line with the KDIGO diag-
nostic AKI criteria (KDIGO 2012).
Nine new studies (Eljezi 2017; Fayaz 2004; Koppert 2006;
McCrory 2002; NAFARM 2011; Ott 2003; POISE-2 2013;
Puolakka 2009; Rafiq 2014) were added to this review.
Types of surgery
Patients underwent various types of surgery: 13 studies reviewed
patients undergoing open cardiac surgery (Eljezi 2017; Fayaz
2004; Hynninen 2000; Immer 2003; Khalil 2006a; Kulik 2004;
McCrory 2002; NAFARM 2011; Ott 2003; Perttunen 1992;
Perttunen 1999; Rafiq 2014; Rapanos 1999) and six studies re-
viewed abdominal or pelvic surgeries (Aitken 1992; Jones 2000;
Power 1992; Puolakka 2009; Turner 1994; Varrassi 1994). The re-
mainder of the studies reviewed patients undergoing orthopaedic,
breast, and various other non-cardiac surgeries.
Interventions
NSAIDs included in the study were ketorolac (Aitken 1992;
Laisalmi 2001a; Perttunen 1992; Perttunen 1999; Rafiq 2014;
Varrassi 1994), indomethacin (Hynninen 2000; Rapanos 1999;
Turner 1994), diclofenac (Fayaz 2004; Hynninen 2000; Immer
2003; Irwin 1995; Perttunen 1992; Perttunen 1999; Power 1992),
aspirin (POISE-2 2013), ibuprofen (Brinkmann 1998; McCrory
2002; Rafiq 2014), naproxen (Kulik 2004), tenoxicam (Jones
2000; Slaven 1998), etodolac (Immer 2003), and ketoprofen
(Eljezi 2017). Selective COX-2 inhibitors were used in four stud-
ies (Khalil 2006a; Koppert 2006; Ott 2003; Puolakka 2009).
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Mode of delivery was via intravenous (IV) or intramuscular (IM)
injection in 15 studies (Aitken 1992; Brinkmann 1998; Eljezi
2017; Jones 2000; Khalil 2006a; Koppert 2006; Kostamovaara
1996; Laisalmi 2001a; Perttunen 1992; Perttunen 1999; Power
1992; Puolakka 2009; Slaven 1998; Varrassi 1994). A combina-
tion of an IV bolus and oral maintenance dose was used by Ott
2003 and Rafiq 2014. The remaining studies used either oral,
epidural or per rectum administration methods. Seven studies pre-
scribed NSAIDs for the first post-operative day only (Fayaz 2004;
Hynninen 2000; Irwin 1995; Laisalmi 2001a; Puolakka 2009;
Rapanos 1999; Varrassi 1994). The median duration of post-op-
erative NSAID exposure was 2 days (range 1 to 30 days).
Measurement of primary outcomes
One study defined AKI using the KDIGO definition (POISE-2
2013) and one using an elevation in SCr of 150% times the base-
line (NAFARM 2011). Creatinine was measured in 15 studies
(Immer 2003; Koppert 2006; Kostamovaara 1996; Kulik 2004;
Laisalmi 2001a; Ott 2003; Perttunen 1992; Perttunen 1999;
POISE-22013; Power 1992; Puolakka 2009;Rafiq 2014;Rapanos
1999; Turner 1994; Varrassi 1994). A percentage change in crea-
tinine from baseline was reported by Eljezi 2017. Change in urine
output post-operatively was reported by seven studies (Aitken
1992; Eljezi 2017; Irwin 1995; Jones 2000; Laisalmi 2001a;
Perttunen 1992; Perttunen 1999). Serum creatinine clearance was
measured by one study (Brinkmann 1998) and urinary creatinine
clearance by four studies (Khalil 2006a; Koppert 2006; McCrory
2002; Slaven 1998).
Measurement of secondary outcomes
Death (all causes) was reported by two studies (NAFARM 2011;
Rafiq 2014); hospital stay by three studies (NAFARM2011; Kulik
2004; Rafiq 2014), and two studies reported the need for RRT
post-operatively (Rafiq 2014; POISE-2 2013).
Excluded studies
Nineteen studies (21 records) were excluded from this review. De-
tails of the reason for exclusion for all of these are found in the
Characteristics of excluded studies table.
Four studies were excluded due to the inclusion of patients with
pre-existing CKD into their cohort (Cheruku 2004; Merry 2002;
Nussmeier 2005; Nussmeier 2006). Two studies published results
about kidney function after nephrectomy (Chow 2001; Grimsby
2012) and were deemed unsuitable for analysis in our review.
Eleven studies were excluded due to lack of concise post-opera-
tive kidney outcomes (Daniels 2014; Fredman 1999;Hynes 2006;
Leeson 2007; Ma 2015; Nuutinen 1991; Parker 1994; Rao 2000;
Ready 1994; Southworth 2009; Varrassi 1999). Two studies were
not suitable for inclusion in this review due to the lack of a suitable
placebo group (Castiglione 1997; Doyle 1998).
Risk of bias in included studies
See Figure 3.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Allocation
Random sequence generation
Nine studies were assessed as low risk, with sufficient information
about the sequence generation process (Fayaz 2004; Jones 2000;
Khalil 2006a; Kulik 2004; NAFARM 2011; Perttunen 1999;
POISE-2 2013; Puolakka 2009; Rapanos 1999). Most commonly
described sequence generation method was computer software. In
the remaining 17 studies randomisation was stated but no infor-
mation was given about the method of sequence generation.
Allocation concealment
Fourteen studies described a randomisation method that was
deemed adequate; investigators or participants did not know or
have influence on the intervention group before entering the study
(Eljezi 2017; Fayaz 2004; Hynninen 2000; Jones 2000; Khalil
2006a; Koppert 2006; Kulik 2004; NAFARM 2011; Perttunen
1999; POISE-2 2013; Puolakka 2009; Rafiq 2014; Rapanos 1999;
Turner 1994). Most commonly used method was sequentially
numbered opaque, sealed envelopes. The remaining 12 studies
did not provide enough information to determine the method of
allocation concealment.
Blinding
Performance bias
All studies mentioned blinding of participants, investigators or
both in their methods section, however in nine studies insufficient
information was provided regarding the methods by which this
was achieved. For that reason those studies were assessed as unclear
risk of performance bias due to the knowledge of the allocated in-
terventions by participants and personnel during the study (Aitken
1992; Brinkmann 1998; Immer 2003; Irwin 1995; Kostamovaara
1996; Laisalmi 2001a; Ott 2003; Power 1992; Varrassi 1994).
Two studies were open-label and were judged to be at high risk of
bias (McCrory 2002; Rafiq 2014). The remaining 15 studies were
judged to be a low risk of bias.
Detection bias
Seven studies were judged to be at low risk bias (Jones 2000;
Kulik 2004; NAFARM 2011; Perttunen 1992; Perttunen 1999;
POISE-2 2013; Turner 1994). One study was classed as high risk
of detection bias (Rafiq 2014), and for the remaining 18 studies
risk of detection bias was judged to be unclear.
Incomplete outcome data
Patient drop-out was reported in 16 studies.
• Protocol violation or equipment failure was the cause of the
drop-out in seven studies (Aitken 1992; Irwin 1995; Koppert
2006; Ott 2003; Rafiq 2014; Rapanos 1999; Turner 1994).
• Side effects of the treatment or complications of the surgery
was the cause for drop-out in five studies (Eljezi 2017: 3 patients
dropped out due to complications of the surgery, reintubation
and/or re-surgery; Kostamovaara 1996: 1 patient dropped out
due to side effect of fentanyl administration, no side effects of
the study drug ketorolac were identified; Kulik 2004: 2 patients
in the naproxen group and 4 patients in the placebo group
suffered from complications after surgery; Rafiq 2014: 21
patients had a prolonged stay in intensive care post surgery -
equally distributed between groups; Varrassi 1994: 5 patients
withdrew due to re-laparotomy or inadequate pain control,
equally distributed over the two groups).
• NAFARM 2011 reported death due to cardiac surgery as
the cause of drop-out in five patients.
• Oliguria or rise in creatinine post operatively was identified
as cause for withdrawal in six studies (Fayaz 2004; Hynninen
2000; Immer 2003; Kulik 2004; Power 1992; Rafiq 2014)
affecting eight patients in total. This is a significant cause for
concern as only three of these studies (Hynninen 2000; Immer
2003; Rafiq 2014) acknowledged the potential effect of the study
medication on kidney function in their conclusion.
Six studies were deemed high risk of attrition bias due to miss-
ing data which potentially has a significant effect on the overall
outcome of the study. Aitken 1992 failed to present the reader
with a reason for missing urine output data in 15 of 61 patients,
while 26% of patients were withdrawn from Ott 2003; mainly
due adverse events. Oliguria and/or rise in creatinine post-oper-
atively was identified as cause for withdrawal from the study in
six studies. Four of these studies (Fayaz 2004; Immer 2003; Kulik
2004; Power 1992) were deemed high risk of bias since these pa-
tients who were particularly at risk of developing AKI (the pri-
mary outcome of this review) were withdrawn from the studies.
Hynninen 2000 also withdrew one patient after one dose of in-
domethacin because of SCr increase > 20% post-operatively. This
patient did not receive furtherNSAIDs as per protocol. This study
was classed as low risk as the patient was not included in the post-
operative outcome table and the plausible effect size of this one
event is probably not enough to have a clinically relevant impact
on observed effect size.
Fifteen studies were judged to be a low risk of attrition bias (Eljezi
2017; Hynninen 2000; Irwin 1995; Jones 2000; Khalil 2006a;
Koppert 2006; Kostamovaara 1996; Laisalmi 2001a; NAFARM
2011; Perttunen 1999; POISE-2 2013; Puolakka 2009; Rafiq
2014; Rapanos 1999; Varrassi 1994). The risk of attrition bias was
unclear in the remaining five studies.
Selective reporting
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Twenty-five studies reported the outcomes that were prespecified
in their methods. Eljezi 2017 failed to report the frequency of uri-
nary output (4-hourly for 48 hours) and creatinine measurements
(baseline, post-operative day 1 and 2) as they had set out to do in
the methods section. Urinary output was documented at 48 hours
only and a percentage change in SCr at 48 hours from baseline was
reported. This study was classed as high risk for reporting bias as
it is unclear whether a potential transient fall in urine output and
rise in creatinine during the first post-operative day has occurred,
which would significantly change the conclusion drawn from this
report.
Other potential sources of bias
Eleven studies reported to have received either no funding or fund-
ing from a non-profit organisation and were therefore deemed
at low risk of publication bias (Eljezi 2017; Kostamovaara 1996;
Kulik 2004; Laisalmi 2001a; McCrory 2002; NAFARM 2011;
Perttunen 1992; Perttunen 1999; Puolakka 2009; Rafiq 2014;
Rapanos 1999). POISE-2 2013 used several sources of funding;
firstly two large governmental non-profit organisations fromSpain
and Australia. Secondly an undefined amount of financial support
as well as study drugs from a commercial body were disclosed.
The authors state that the sponsors had no role in the design and
conduct of the study, collection, management, analysis, review or
approval of themanuscript; and decision to submit themanuscript
for publication. Due to the combination of commercially as well
as non commercially accrued funding sources used in this study,
in combination with the extensive disclosure of the use of the
commercially acquired funding, this study was classed as low risk.
Slaven 1998 received the study drug and placebo as a gift from the
manufacturer, however the study design and analysis of the results
was independent of any company involvement and was judged to
be at low risk of bias.
Six studies were classed as high risk of bias due to the use of com-
mercial funding. An unknownquantity of financial support from a
commercial body was received by three studies (Jones 2000; Khalil
2006a; Koppert 2006). Aitken 1992 received financial support as
well as study drugs from a pharmaceutical company. Commer-
cially provided study drugs were used by Immer 2003. Other po-
tential biases were unclear in the remaining eight studies.
Effects of interventions
See: Summary of findings for the main comparison
Nonsteroidal anti-inflammatory drugs (NSAIDs) versus placebo
or no treatment in the peri-operative period
See Summary of findings for the main comparison for main com-
parisons.
Post-operative acute kidney injury
One large study (6905 participants) POISE-2 2013 reported AKI
defined by the KDIGO criteria and one smaller study (161 par-
ticipants) NAFARM 2011 defined AKI as a rise of SCr of 150%
times the baseline. The use of NSAIDs had uncertain effects on
the incidence of AKI compared to placebo (Analysis 1.1 (2 studies,
7066 participants): RR 1.79, 95% CI 0.40 to 7.96; I2 = 59%; very
low certainty evidence). The analysis was dominated by POISE-2
2013 with 70.4% of the weighting and medium level of hetero-
geneity. NAFARM 2011 was terminated early by the trial moni-
toring committee because of increased risk of AKI.
Post-operative serum creatinine
Change in SCr was reported in 15 studies. AKI is defined as peak
post-operative SCr and so where creatinine was measured over
several time points, peak SCrwas used for the analysis. In addition,
where several differentNSAIDs or dosing regimenswere compared
in a study, the regime or drug with the greatest adverse effect
on kidney function was included within the analysis. Ott 2003
defined kidney dysfunction as a creatinine value > 177 µmol/L
and an increase of 62 µmol/L with an incidence of 2.6% in both
groups. This study was not included in the pooled analysis due to
the lack of absolute values.
Compared to placebo, NSAIDs may slightly increase serum SCr (
Analysis 2.1 (15 studies, 794participants):MD3.23 µmol/L, 95%
CI -0.80 to 7.26; I2 = 66%; low certainty evidence).Heterogeneity
was medium to high.
Meta-regression of change in post-operative serum
creatinine by pre-specified effect modifiers
Of the 15 studies in the meta-analysis of change in post-operative
SCr (Analysis 2.1), seven studies were in cardiac surgery, eight with
> 24 hours of NSAID use, and nine with no stated age exclusion
(Table 1). As expected cardiac surgery and > 24 hours of NSAID
use were associated with a positive beta (greater effect size) in the
meta-regression (Figure 1). In contrast, we expected that RCTs
with no stated age exclusion would have greater effect size but beta
was negative (lower effect size) for these RCTs in the univariate
meta-regression (Figure 1). Multivariate analysis did not identify
significant effect modifiers (Figure 1).
Sensitivity analyses
Exclusion of studies with an overall high risk of bias (Analysis 2.2),
high risk of attrition bias (Analysis 2.3) and either high overall
risk of bias or high risk of attrition bias (Analysis 2.4) reduced the
effect estimate.
Post-operative urine output
Change in urine output was measured in seven studies. Eljezi 2017
measured urine output at 48 hours but did not report baseline
urine output. Where urine output was measured over several time
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points, lowest post-operative urine output was used for the analy-
sis. Urine output was measured as total volume, mL/min and mL/
kg/h therefore standardised mean difference (SMD) was used for
pooling the data.
NSAIDs may make little or no difference to post-operative urine
output compared to placebo (Analysis 3.1 (6 studies, 149 partic-
ipants): SMD -0.49, 95% CI -1.21 to 0.24; I2 = 77%; low cer-
tainty evidence) Heterogeneity was high. The differences in units
of measurements and time points when urine output was mea-
sured in the different studies rendered interpretation of these re-
sults difficult.
Need for renal replacement therapy
Two studies reported the need for RRT (POISE-2 2013; Rafiq
2014). It is uncertain whether NSAIDs leads to the need for RRT
because the certainty of this evidence is very low (Analysis 4.1 (2
studies, 7056 participants): RR 1.57, 95% CI 0.49 to 5.07; I2 =
26%). Heterogeneity was low.
Death (all causes)
Two studies reported death (NAFARM 2011; Rafiq 2014). It is
uncertain whether NSAIDs leads to more deaths because the cer-
tainty of this evidence is very low. These were two small studies
with a small number of events (Analysis 5.1 (2 studies, 312 partic-
ipants): RR 1.44, 95%CI 0.19 to 11.12; I2 = 38%) Heterogeneity
was low to medium.
Length of hospital stay
Three studies examined length of hospital stay (NAFARM 2011;
Kulik 2004; Rafiq 2014). It is uncertain whetherNSAIDs result in
a longer hospital stay because the certainty of this evidence is very
low (Analysis 6.1 (3 studies, 410 participants): MD 0.12 days,
95% CI -0.48 to 0.72; I2 = 24%). Heterogeneity was low.
D I S C U S S I O N
Summary of main results
We included 26 eligible studies (8943 participants) examining
the use of NSAIDs in the perioperative period in patients with
normal kidney function. The primary outcome of AKI, defined
by KDIGO creatinine-based criteria, was used in only two stud-
ies. Change in SCr was measured in 14 studies and urine out-
put in seven. For the secondary outcomes, two studies examined
RRT, two examined death, and two length of hospital stay. Type
of surgery, duration of treatment and dosage varied among the
studies. Kidney outcomes were secondary outcomes in 13 studies.
Two studies examined the use of NSAIDs for indications other
than analgesia (NAFARM 2011; POISE-2 2013) and the NSAID
doses were lower than would be used as analgesia. Overall risk
of bias was high in 17, unclear in six studies and low in three
studies. Overall NSAIDs had uncertain effects on the risk of post-
operative AKI, may slightly increase post-operative SCr, and it is
uncertain whether NSAIDs leads to the need for RRT, death or
increases the length of hospital stay (Summary of findings for the
main comparison)
The two studies with AKI as a primary outcome were the largest
studies in the review and had few exclusions (NAFARM 2011;
POISE-2 2013). One study was stopped by the data monitoring
committee because of increased risk of post-operative AKI in the
NSAID group (NAFARM 2011). The indication for NSAID use
was to reduce risk of post-operative atrial fibrillation. The dose
of naproxen (550 mg/d) was below the lowest daily dose recom-
mended for analgesia for osteoarthritis (750 mg/d; Chou 2011)
and substantially lower than the dose of 1000 mg/d used for post-
operative analgesia in another study in our review (Kulik 2004).
The contrast between the results of NAFARM 2011 and Kulik
2004 is striking. Both studies used the same NSAID (naproxen)
for the same duration (four days) in the same patient group (coro-
nary artery bypass graft surgery). However, despite using a much
lower dose of naproxen, NAFARM 2011 was stopped because of
increased risk of post-operative AKI whereas Kulik 2004 reported
that naproxen use was associated with a mean decrease in post-
operative SCr. POISE-2 2013 aimed to reduce the risk of post-op-
erative AKI in patients undergoing elective or emergency surgery
and included 6905 patients from 22 countries. The aspirin group
received 200 mg on the day of surgery and then 100 mg/d for
seven days, whereas the maximum recommended daily dose of
aspirin is 4000 mg (NICE 2017).
Compared to placebo, NSAIDs may slightly increase serum SCr
(3.23 µmol/L, 95% CI -0.80 to 7.26). Studies displayed moder-
ate to high heterogeneity with multiple different exclusion crite-
ria (e.g. age, diabetes, heart failure, use of diuretics) and so were
not representative of patients undergoing surgery. Three of these
studies excluded patients if their creatinine rose post-operatively.
No reliable conclusions could be drawn from the studies examin-
ing urine output due to the differing units of measurements and
measurement time points.
It is uncertain whether the use of NSAIDs leads to an increased
need for RRT, more deaths, or increased length of hospital stay.
Overall completeness and applicability of
evidence
There are significant limitations to this review. Most of the stud-
ies excluded patients with co-morbidities such as diabetes, heart,
liver, or respiratory failure. The population studied was therefore
highly selected and non-representative of the population of pa-
tients undergoing surgery in most hospitals. With the exception
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of one study (POISE-2 2013), the studies were small and hetero-
geneous examining various types of NSAIDs, various doses and
different types of surgery. A further important limitation was that
three studies (Fayaz 2004;Hynninen 2000; Immer 2003) excluded
patients if their SCr rose post-operatively and one study (Power
1992) administered furosemide to patients if their post-operative
urine output fell. This impacts on the outcomes of these studies
as they included both SCr and urine output.
The largest study (POISE-2 2013) examined the kidney effects of
aspirin for an indication other than analgesia in 6905 patients un-
dergoing surgery. Types of surgery included major vascular, tho-
racic, urological, and gynaecological. Patients with co-morbidities
such as diabetes and cardiovascular disease were included. There
were also patients with CKD included. Patients received aspirin
at very low dose (100 mg/d; NICE 2017) and was associated with
an uncertain effect on post-operative AKI (Analysis 1.1) and RRT
(Analysis 4.1). The risk difference for RRTwas 3 patients per 1000
treated (95% CI 0 to 6). Inclusion of this large study impacted
significantly on the findings of this review.
Quality of the evidence
We identified 26 eligible RCTs with 8835 participants examining
the use of NSAIDs in the perioperative period in patients with
normal kidney function. Risk of bias was high in 17, unclear in
6studies and low in 3 studies with high risk of attrition bias in 6
studies.
We have graded the evidence that NSAIDs increase the risk of
post-operative AKI as very low certainty (Summary of findings for
the main comparison). These were the largest RCTs in the review
and both were low risk of bias (NAFARM 2011, POISE-2 2013).
Importantly, both trials included patients with co-morbidities and
both studies used NSAIDs at relatively low doses for non-anal-
gesic indications. Our main concern was about the inconsistencies
between the two studies. Risk of AKI in the control groups were
completely different (1.2% in NAFARM 2011 versus 12.3% in
POISE-2 2013).
We graded the evidence about increase in post-operative SCr as
low certainty. The certainty of evidence was downgraded because
of inconsistency (heterogeneity was not adequately explained by
pre-specified effect modifiers) and indirectness (studies had multi-
ple exclusion criteria with the patients included in the RCTs likely
to be different from those in routine care). The results of Kulik
2004 (decrease in SCr associated with naproxen for 5 days after
cardiac surgery) are in stark contrast to the results of NAFARM
2011 (study stopped because of excess risk of AKI associated with a
lower dose of naproxen for 5 days after cardiac surgery). There was
potential for publication bias as studies were small and commer-
cially funded. However, the Funnel Plot was symmetrical (Figure
4). For the outcome of RRT, certainty of evidence was very low.
This was downgraded because of imprecision, inconsistency and
publication bias. There was imprecision due to low number of
events, inconsistency as the risk of RRT was completely different
in the two control groups (0.3% in NAFARM 2011 versus 2.7%
in Rafiq 2014) and publication bias as one of the two studies was
small and commercially funded.
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Figure 4. Funnel plot of comparison: 2.1 Mean difference in serum creatinine
We were concerned that studies with high risk of bias would un-
derestimate the effect of NSAIDs on post-operative kidney func-
tion. However, sensitivity analysis of post-operative SCr increase
showed that exclusion of studies with high risk of overall bias or
attrition bias reduced the study effects (Analysis 2.2; Analysis 2.3;
Analysis 2.4).
Potential biases in the review process
The review was conducted with standard Cochrane methodology.
The review was completed independently by two authors, who
participated in all steps of the review. This limited the risk of er-
rors in determining study eligibility, data extraction, risk of bias
assessment and data synthesis. We did not include the results of
unpublished studies. Studies with both positive and negative re-
sults were identified, making the possibility of publication bias less
likely. A strength of this review is that we included studies defining
AKI using the KDIGO definition KDIGO 2012.
Agreements and disagreements with other
studies or reviews
Lee 2007 concluded that NSAIDs caused a clinically unimpor-
tant reduction in kidney function on the first post-operative day
in patients with normal kidney function. They examined several
surrogate measures for kidney function including urinary sodium
and CrCl. CrCl estimations are based on steady state measure-
ments and so are inaccurate in AKI with fluctuating creatinine
levels. Lee 2007 found a reduction in CrCl of 16 mL/min (95%
CI 5 to 28) in patients treated with NSAIDs. Since this review,
there is now a universally agreed definition for AKI based on SCr
or urine output which has been adopted by KDIGO (KDIGO
2012). The studies included in the previous review also excluded
patients with co-morbidities and so these results cannot be applied
to the general population undergoing surgery as many these will
be older patients with co-morbidities.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of evidence about the safety of NSAIDs used in the
peri-operative period in all patients; patients with co-morbidities
were excluded and NSAIDs had uncertain effects on AKI and the
need for RRT. Whilst, NSAIDs may be safely used in fit, healthy
patients, care should be employed in high risk patients. We were
unable to identify which patients are at risk based on the results of
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this review and so clinical judgement should be employed based
on the individual and alternative analgesic strategies may need to
be employed in selected cases.
Implications for research
Our analysis was limited to small studies excluding patients with
co-morbidities. Several of the studies were designed to investigate
AKI as a secondary outcome and used varying definitions for AKI.
The indication for NSAID was not analgesia in all of the stud-
ies and the doses varied. Several studies excluded patients if their
creatinine rose post-operatively or their urine output fell. Further
larger studies using the KDIGO definition for AKI including pa-
tients with co-morbidities are required to confirm our findings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aitken 1992
Methods • Study design: RCT
• Study duration: not reported
• Study follow-up: 48 h
Participants • Country: UK
• Setting: single centre
• Inclusion criteria: undergoing elective upper abdominal surgery
• Number: treatment group 1 (19); treatment group 2 (23); control group (21)
• Mean age (years): treatment group 1 (47.2); treatment group 2 (48.6); control
group (56.1)
• Sex (M/F): treatment group 1 (19/10); treatment group 2 (10/13); control group
(10/11)
• Exclusion criteria: respiratory insufficiency hepatic or kidney impairment; abuse
of alcohol or drugs
Interventions Treatment group 1
• Ketorolac: 12.5 mg/h IM infusion for 30 min during surgery then 2.5 mg/h for
47.5 h, with normal saline injections every 4 h
Treatment group 2
• Ketorolac: 10 mg every 4 h IM for 48 h, first dose during surgery
Control group
• Intermittent and continuous infusions of saline to match other groups
Outcomes • Pre-operative and post-operative CrCl, urine output, sodium output, potassium
output
Notes • Funding Source: Syntex research gave financial assistance and supplied the study
drugs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as “double-blind”; insuffi-
cient information to permit judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk 67 patients were randomised, of which 63
patients were included in the patient data
table
Six patients were withdrawn from the study
after 24 or 48 h of treatment due to equip-
ment failure or on patient’s request. No
data on randomisation of the withdrawn
patients
Of remaining 61 patients there is miss-
ing data from 15 patients, probably equally
distributed amongst the intervention and
placebo groups
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias High risk A commercial funding source was used for
this study
Brinkmann 1998
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 24 h
Participants • Country: Germany
• Setting: single centre
• Inclusion criteria: elective infrarenal aortic surgery
• Number: treatment group (67); control group (64)
• Mean age ± SD (years): treatment group (13 ± 2); control group (13 ± 3)
• Sex (M/F): treatment group (11/2); control group (11/2)
• Exclusion criteria: NSAID medication at least 7 days prior to surgery; history of
significant renal disease; evidence for renal artery stenosis on preoperative aortography.
Interventions Treatment group
• Ibuprofen: 400 mg IV before skin incision
Control group
• Placebo: aliquot IV before skin incision
Outcomes • CrCl, and fractional sodium excretion before surgery, 1 h after cross-clamping, 6
h after cross-clamping and 24 h after cross-clamping (on the 1st postoperative day).
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Notes • Funding Source: not reported
• Furosemide was given in post-operative period in 5 patients (treatment group 3/
13, control group 2/13), indication for administration unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk All intended measurements were reported
at baseline, 1 and 6 hours after cross-clamp-
ing, and on the first POD
Other bias Unclear risk The study was conducted by the anaesthet-
ics department of the University of Ulm.
There is no mention of funding sources
Eljezi 2017
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 48 h
Participants • Country: France
• Setting: inpatient
• Inclusion criteria: patients undergoing elective open heart surgery or coronary
artery bypass grafting
• Number: treatment group 1 (25); treatment group 2 (25); treatment group 3 (24)
control group (23)
• Mean age ± SD (years): treatment group 1 (63 ± 9); treatment group 2 (63. ± 7);
treatment group 3 (60 ± 11); control group (58 ± 13)
• Sex (M/F): treatment group 1 (23/2); treatment group 2 (22/3); treatment group
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3 (24/0) control group (12/11)
• Exclusion criteria: kidney insufficiency defined as a CrCl < 60 mL/min−1; hepatic
insufficiency; congestive heart failure with ejection fraction < 45%; history of gastric
peptic ulcer or GI bleeding; DM needing insulin therapy; preoperative coagulation
disorder; allergy to NSAID; pregnancy or breastfeeding
Interventions Treatment group 1
• IV ketoprofen: 0.5 mg/kg every 6 h for 48 h
Treatment group 2
• IV ketoprofen 0.25 mg/kg every 6 h for 48 h
Treatment group 3
• IV ketoprofen: 0.125 mg/kg every 6 h for 48 h
Control group
• IV normal saline
Outcomes • Pre-operative SCr then SCr level at POD 1 and POD 2
• Urine output every 4 h until 48 h post-operatively
Notes • Only 48 h SCr and urine output results documented
• 100 patients randomised, 97 patient analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Allocation was concealed in an envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study drug was prepared by an anaes-
thetist nurse not involved of post-operative
care, under the control of the anaesthetist
in charge of the patient, who opened the
allocation envelope
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is no incomplete data
Selective reporting (reporting bias) High risk Methods state 4 hourly urinary output
measurements until 48 h post-operatively
and SCr measurement for POD 1 and
POD 2. No urinary output results docu-
mented for 0 - 44 h. SCr documented at
baseline and a percentage rise at 48 h re-
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ported. No results for POD 1 reported
Other bias Low risk The study was conducted by the Depart-
ment of Anesthesiology (Medecine Peri-
Operatoire) and theClinical Pharmacology
centre (CPC-CIC) of the University Hos-
pital of Clermont-Ferrand (CHU Cler-
mont-Ferrand), France. The sponsorship
was limited to supplies and expenses. The
sponsorship included payment for employ-
ees for study design, patient’s inclusion,
data entry, and analysis of the data. They
also provided the study drugs at no cost.
They had no influence or interference after
the protocol was designed
Fayaz 2004
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 24 h
Participants • Country: UK
• Setting: single centre
• Inclusion criteria: patients undergoing coronary artery bypass graft surgery
• Number: treatment group 1 (17); treatment group 2 (17); control group (20)
• Mean age ± SD (years): treatment group 1 (59.4 ± 8.4); treatment group 2 (64.0 ±
8.4); control group (64.3 ± 7.9)
• Sex (M/F): treatment group 1 (9/7); treatment group 2 (11/6); control group (9/
9)
• Exclusion criteria: previous history of peptic ulcer disease or GI bleeding; hepatic
and/or kidney insufficiency (SCr > 120 µmol/L); insulin-dependent DM; left
ventricular ejection fraction 30%; weight > 110 kg or < 55 kg; known allergy to study
drugs.
• Post-operative exclusion criteria: patients with prolonged cardiopulmonary bypass
(180 min), patients requiring intra-aortic balloon pump support, patients who had
excessive post-operative bleeding 150 mL/h for the first 2 h, and patients with early
post-operative SCr increase (20% of baseline)
Interventions Treatment group 1
• Diclofenac: 100 mg
• Paracetamol: 1 g
• Suppositories were administered 2 h after surgery. Diclofenac was repeated after
18 h and paracetamol every 6 h for 24 h
Treatment group 2
• Diclofenac: 100 mg, 2 and 18 h after surgery
Control Group
• Placebo suppositories: 2 at same time as treatment group 1
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Outcomes • SCr
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization code was computer
generated by Lab View version 2”
Allocation concealment (selection bias) Low risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Drugs made up by pharmacist
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/60 patients withdrawn. Equally dis-
tributed across study groups and similar
reasons for withdrawal given. 2 patients
were withdrawn before entering the study
due to oliguria and an early post-operative
SCr rise (> 20% from baseline)
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Unclear risk Insufficient information to permit judge-
ment
Hynninen 2000
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 24 h
Participants • Country: Canada
• Setting: inpatient
• Inclusion criteria: patients undergoing coronary artery bypass graft surgery were
randomised.
• Number: treatment group 1 (28); treatment group 2 (28); treatment group 3 (27)
; control group (31)
• Mean age ± SD (years): treatment group 1 (59 ± 9); treatment group 2 (60 ± 7);
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treatment group 3 (58 ± 9); control group (55 ± 9)
• Sex (M/F): treatment group 1 (20/8); treatment group 2 (24/4); treatment group
3 (21/6); control group (28/3)
• Exclusion criteria: ejection fraction < 20%; previous cardiac surgery; insulin-
dependent DM; weight > 100 kg or < 60 kg; kidney insufficiency (SCr > 130 µmol/L);
allergy to propofol, morphine or NSAID; active peptic ulcer disease; history of GI
bleeding; age > 75 years; warfarin, dipyridamole or heparin therapy preoperatively
Interventions Treatment group 1
• Diclofenac: 75 mg suppository twice/d after surgery
Treatment group 2
• Ketoprofen: 100 mg suppository twice/d after surgery
Treatment group 3
• Indomethacin: 100 mg suppository twice/d after surgery
Control group
• Placebo suppository twice/d after surgery
Outcomes • Pre-operative and post-operative SCr
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Randomisation and preparation of study
drug in identically shaped suppositories
was done by hospital pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Randomisation and preparation of study
drug in identically shaped suppositories
was done by hospital pharmacy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/114 patients withdrawn. Of these six pa-
tients, 1 patient was withdrawn after one
dose of indomethacin because of SCr in-
crease > 20% post-operatively. This patient
did not receive further NSAIDs as per pro-
tocol and was not included in the post-op-
erative outcome table. This event was men-
tioned in the discussion of the paper. The
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plausible effect size of this one event is prob-
ably not enough to have a clinically relevant
impact on observed effect size
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Unclear risk Insufficient information to permit judge-
ment
Immer 2003
Methods • Study design: parallel RCT
• Study duration: June 2000 to October 2000
• Study follow-up: until hospital discharge
Participants • Country: Switzerland
• Setting: single centre
• Inclusion criteria: patients undergoing coronary artery bypass operation
• Number: treatment group 1 (20); treatment group 2 (20); control group (20)
• Mean age ± SD (years): treatment group 1 (56.6 ± 8.8); treatment group 2 (60.5 ±
6.1); control group (60.5 ± 8.5)
• Sex (M/F): treatment group 1 (3/17); treatment group 2 (3/17); control group (5/
15)
• Exclusion criteria: > 70 years; left ventricular ejection fraction < 30%; previous
history of peptic ulcer disease or GI bleeding; hepatic or kidney insufficiency; known
allergy to tramadol or NSAIDs and preoperative analgesic treatment
• Post-operative period exclusion criteria: delayed transfer to the general ward; SCr
more than 150 µmol/L, and altered mental status
Interventions Treatment group 1
• Diclofenac: 50 mg every 8 h orally on POD 2 and 3
Treatment group 2
• Etodolac: 300 mg every 8 h orally on POD 2 and 3
Control group
• Tramadol: slow-release (150 mg every 12 h orally)
Outcomes • Pre-operative and post-operative SCr
Notes • Tramadol group (weak opioid) not included in analysis
• POD 1 SCr data not included as study drugs were not given
• CrCl measured on POD 4
• Funding Source: Study drugs were supplied by Grunenthal, Novartis Pharma and
Sigma-Tau, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 out of 69 patients were excluded post-
operatively, prior to randomisation. One of
these patients was withdrawn due to a post-
operative SCr rise (> 150 µmol/L)
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias High risk A commercial funding source was used for
this study
Irwin 1995
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 48 h post-operatively
Participants • Country: Hong Kong
• Setting: single centre
• Inclusion criteria: males undergoing elective minor orthopaedic surgery
• Number: treatment group (11); control group (10)
• Mean age ± SD (years): treatment group (45.6±19.0); control group (33.5±9.5)
• Sex (M/F): not reported
• Exclusion criteria: patients with respiratory, cardiac, hepatic or kidney
insufficiency; history of peptic ulcer disease or allergy to aspirin, diclofenac or other
prostaglandin inhibiting compounds
Interventions Treatment group
• Diclofenac: 100 mg suppository before surgery then 100 mg at 8am on day 1
Control group
• Placebo: suppository before surgery and at 8am on day 1
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Outcomes • Pre-operative and post-operative (at 24 h and 48 h) measurements of CrCl, urine
output, sodium output, potassium output, fractional excretion of sodium, fractional
excretion of potassium
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient withdrew from study; reason
for missing outcome data unlikely to be re-
lated to outcome
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Unclear risk Insufficient information to permit judge-
ment
Jones 2000
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 96 h post-operatively
Participants • Country: Australia
• Setting: single centre
• Inclusion criteria: women aged 50 to 70 years undergoing major gynaecological
surgery (ovarian, uterine or cervical cancer)
• Number: treatment group (15); control group (15)
• Mean age ± SD (years): treatment group (60.3 ± 6.3); control group (60.3 ± 6.9)
• Sex (M/F): All female
• Exclusion criteria: kidney or hepatic impairment; bleeding diathesis;
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hypersensitivity to NSAIDs; asthma; medications known to interfere with tenoxicam
disposition
Interventions Treatment group
• Tenoxicam: 20 mg IV given 2 h before surgery
Control group
• Normal saline: IV given 2 h before surgery
Outcomes • Pre-operative and post-operative (at 2, 24, 48, 72, and 96 h) measurements of
CrCl, SCr, fractional excretion of sodium and potassium
Notes • Funding source: unknown quantity of support provided by Hoffmann-La Roche
& Co, Basle, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Roche pharmaceuticals coded and allo-
cated 30 patients using random number ta-
bles
Allocation concealment (selection bias) Low risk Study drugs made up by Roche pharma-
ceuticals
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The allocation was not released until the
end of clinical data collection
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The allocation was not released until the
end of clinical data collection
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias High risk A commercial funding source was used for
this study
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Methods • Study design: RCT
• Study duration: 2 years
• Study follow-up: 48 hours
Participants • Country: UK
• Setting: single centre
• Inclusion criteria: elective coronary artery bypass grafting
• Number: treatment group (21); control group (19)
• Mean age ± SD (years): treatment group (56.7 ± 9.1); control group (58.8 ± 6.6)
• Sex (M/F): not reported
• Exclusion criteria: diabetics; on anticoagulants; previous cerebrovascular disease
Interventions Treatment group
• Parecoxib: single IV dose of 40 mg given at closure of sternotomy
Control group
• Placebo: single IV dose given at closure of sternotomy
Outcomes • 24 hour urinary CrCl, urinary a-1-microglobulin
Notes • Funding: Pharmacia
• Furosemide given in post-operative phase for oliguria; (treatment 12/21 patients,
control 9/19 patients)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisationusing a num-
ber generator
Allocation concealment (selection bias) Low risk A third party placed the results of the ran-
domisation in sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Envelopes were opened at close of the
surgery and a third party prepared the study
medication (placebo or treatment) which
looked identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Initial power calculations resulted in an in-
tended study population size of 60 patients.
Following a global announcement of Pfizer
that parecoxib was ‘contraindicated in pa-
tients with ischaemic heart disease’ further
inclusion in the studywas terminated at 40.
Data of all 40 patients is presented
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Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias High risk Commercial funding source Pharmacia,
which is the manufacturer of Parecoxib
Koppert 2006
Methods • Study design: parallel RCT
• Study duration: 2002 to 2003
• Study follow-up: 3 POD
Participants • Country: Germany
• Setting: single centre
• Inclusion criteria: elderly patients ≥ 85 years undergoing hip replacement or
surgery of the femoral shaft
• Number: treatment group 1 (25); treatment group 2 (25); control group (25)
• Mean age ± SD (years): treatment group 1 (76.0 ± 8.0); treatment group 2 (76.7 ±
8.9); control group (76.7 ± 8.6)
• Sex (M/F): treatment group 1 (9/16); treatment group 2 (14/11); control group
(11/14)
• Exclusion criteria: angina or congestive heart failure; recent history of MI,
coronary angioplasty, coronary arterial bypass, stroke or transient ischaemic attack;
uncontrolled hypertension or uncontrolled DM; kidney disease; bleeding disorders;
any disease that the investigator believed would pose a risk to the patient
Interventions Treatment group 1
• Parecoxib: 40 mg and 12 hourly subsequently
Treatment group 2
• IV paracetamol: infusion of 1000 mg and 6 hourly subsequently
Control group
• IV saline: over 10 min
Outcomes • Differences in CrCl pre-operatively and up to 6 h post-operatively
Notes • Funding source: unknown quantity of support provided by Bristol-Myers Squibb
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk All study medication solutions were pre-
pared by a hospital pharmacist who was not
involved in the data collection
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The anaesthesiologist, nursing staff, and
the investigators were all blinded to the
treatment. At the surgical ward, patients
and nursing staff were unblinded to the
medication
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eight of 83 patients withdrew from study.
Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias High risk A commercial funding source was used for
this study
Kostamovaara 1996
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 2 POD
Participants • Country: Finland
• Setting: single centre
• Inclusion criteria: patients undergoing total hip (62) or knee (14) replacement
• Number: treatment group 1 (19); treatment group 2 (20); treatment group 3 (18)
control group (19)
• Mean age ± SD (years): treatment group 1 (61 ± 10); treatment group 2 (58 ± 8);
treatment group 3 (64 ± 5) control group (61 ± 7)
• Sex (M/F): treatment group 1 (5/14); treatment group 2 (10/10); Treatment
group 3 (15/3); control group (6/13)
• Exclusion criteria: hepatic, kidney or cardiac failure; bleeding or coagulation
disorders; peptic ulcer; asthma; hypersensitivity to aspirin or other NSAIDs; on
cytostatic treatment
Interventions Treatment group 1
• Ketoprofen: 50 mg IV loading dose for 30 min, followed 50 mg infusion over
following 11.5 h
Treatment group 2
• Ketoprofen: 100 mg IV loading dose for 30 min, followed 100 mg infusion over
following 11.5 h
Treatment group 3
• Ketoprofen: 150 mg IV loading dose for 30 min, followed 150 mg infusion over
following 11.5 h
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Control group
• Isotonic saline: IV infusion for 30 min, followed by saline over following 11.5 h
Outcomes • Pre-operative and day 2 SCr
Notes • Funding source: Grant awarded by the Professor Arno Hollmen Fund, Finland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three of 76 patients withdrawn from
study; reasons for missing outcome data
unlikely to be related to true outcome
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Non-profit organisation funding received
Kulik 2004
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 4 POD
Participants • Country: Canada
• Setting: single centre
• Inclusion criteria: patients undergoing elective coronary artery bypass graft
• Number: treatment group (50); control group (48)
• Mean age ± SE (years): treatment group (58.9 ± 1.5); control group (60.8 ± 1.4)
• Sex (M/F): treatment group (46/4); control group (45/3)
• Exclusion criteria: left ventricle ejection fraction < 20%; SCr > 130 µmol/L;
preoperative use of H2 antagonists, proton pump inhibitors, steroids, NSAIDs (with
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exception of aspirin), narcotics or illicit drugs; history of peptic ulcer, liver disease or
NSAID allergy
Interventions Treatment group
• Naproxen: 500 mg rectal suppository within 1 h after arrival in the recovery room,
then every 12 h for a total of 5 doses; followed by 250 mg orally 3 times/d for 2 days
Control group
• Placebo: suppositories and tablets administered in a similar way as the treatment
group
Outcomes • Pre-operative and post-operative SCr, inotropic use for kidney dysfunction
Notes • 16 patients withdrawn: 7 did not receive naproxen because of prolonged
cardiopulmonary bypass time, perioperative stroke, anorexia and protocol violations; 9
did not receive placebo because of cardiac arrest, perioperative MI, elevated baseline
SCr, excessive chest tube output and protocol violations
• Funding source: no funding received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation
Allocation concealment (selection bias) Low risk Medication was prepared by hospital phar-
macy and appeared identical
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medication administration and data collec-
tion were done in a double blinded fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication administration and data collec-
tion were done in a double blinded fashion
Incomplete outcome data (attrition bias)
All outcomes
High risk 16 of 98 patients withdrawn from the
study, of these one patient had a baseline
creatinine of 115 µmol/L pre-operatively.
Remainder of the reasons for missing out-
come data unlikely to be related to true out-
come
Despite 16 patients did not receive the in-
tervention as allocated on randomisation
- post-operative results of all 98 patients
presented. The plausible effect size among
missing outcomes enough to induce clini-
cally relevant bias in observed effect size
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Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk The study appears to be free of other
sources of bias
Laisalmi 2001a
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 2 POD
Participants • Country: Finland
• Setting: single centre
• Inclusion criteria: ASA physical status I-II women scheduled to undergo elective
breast surgery
• Number: treatment group (15); control group (15)
• Mean age ± SD (years): treatment group (49 ± 7); control group (45 ± 9)
• Sex (M/F): all female
• Exclusion criteria: patients with abnormal kidney or hepatic function
Interventions Treatment group
• 30 mg ketorolac: 30 mg IM with the premedication, “at the end of,” and 6 h after
anaesthesia
Control group
• Saline: 3 IM injections
Outcomes • Kidney function was assessed using sensitive markers that monitor the function of
different entities of the kidney at after 2h of anaesthesia, 2 and 12h after the end of
anaesthesia, as well as on the first and on the second POD: U-NAG/creat for proximal
tubular function, PuO2 is a marker of medullary homeostasis, and EPO that of the
tubulointerstitium
• The traditional function markers such as SCr and urea were also measured at 12 h
after the end of anaesthesia, and on the first and second POD
• Urine output
Notes • Funding Source: Helsinki University Central Hospital EVO Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Non-profit organisation funding received
McCrory 2002
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: until 72 h post follow-up from ICU
Participants • Country: Ireland
• Setting: single centre
• Inclusion criteria: elective thoracic surgery via thoracotomy
• Number
◦ Spinal: treatment group 1 (10); treatment group 2 (10); control group (10)
◦ Epidural: treatment group 1 (5); treatment group 2 (5); control group (5)
• Mean age ± SD (years)
◦ Spinal: treatment group 1 (64 ± 4), treatment group 2 (63 ± 2), control (62
± 2)
◦ Epidural: treatment group 1 (58 ± 6), treatment group 2 (56 ± 8), control
(66 ± 3)
• Sex (M/F)
◦ Spinal: treatment group 1 (6/4); treatment group 2 (5/5); control group (6/4)
◦ Epidural: treatment group 1 (3/2); treatment group 2 (3/2); control group
(3/2)
• Exclusion criteria: history of peptic ulcer disease; renal and hepatic dysfunction;
psychiatric illness; any chronic pain syndrome; and consumption of NSAIDs,
corticosteroids, or any other drug known to interfere with prostaglandin production
for 14 days before surgery.
Interventions Two types of administration - spinal and epidural. Each were assigned to following 3
groups
Treatment group 1
• Nimesulide: 100 mg twice daily
Treatment group 2
• Ibuprofen: 400 mg 4 times daily
40Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCrory 2002 (Continued)
Control group
• No NSAIDs or placebo
Outcomes • 24 h urinary creatinine
Notes • Funding Source: Baggott Street Hospital Academic Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Anaesthetists and patients did have knowl-
edge of the study and allocated treatment
group. This knowledge is unlikely to influ-
ence the primary renal outcome; 24 hour
urinary creatinine
Nursing staff was unaware of patients par-
ticipating in the study and will therefore
not impact on the pain score outcomes pre-
sented
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Study conducted in a university teach-
ing hospital, non-profit academic research
grand received
NAFARM 2011
Methods • Study design: parallel RCT
• Study duration: 2005 to 2009
• Study follow-up: until hospital discharge
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NAFARM 2011 (Continued)
Participants • Country: Brazil
• Setting: single centre
• Inclusion criteria: patients undergoing coronary artery bypass graft surgery
• Number: treatment group (82); control group (79)
• Mean age ± SD (years): treatment group (59.7 ± 9.8); control group (58.0 ± 8.6)
• Sex (M/F): treatment group (50/32); control group (52/27)
• Exclusion criteria: allergies to study medication; pregnant; off-pump surgery;
history of GI bleeding; chronic liver disease; kidney insufficiency (SCr > 132.6 mol/L);
thrombocytopenia; reported preoperative use of glucocorticoids; previous diagnosis of
atrial fibrillation
Interventions Treatment group
• Naproxen: 275 mg twice/d for 5 days from the moment the patients returned to
the ICU post surgery
Control group
• Placebo: twice/d for 5 days from the moment the patients returned to the ICU
post surgery
Outcomes • Kidney failure (SCr elevation ≥ 50% from baseline)
• Death
• Length of hospital stay
Notes • Funding source: no funding received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The pharmacist made the randomization
list and allocated the placebo and naproxen
pills without the knowledge of any other
person”
Allocation concealment (selection bias) Low risk Sealed envelope, medication appears iden-
tical, nursing staff giving out drugs are not
part of the investigation team
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Sealed envelope, medication appears iden-
tical, nursing staff giving out drugs are not
part of the investigation team
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Sealed envelope, medication appears iden-
tical, nursing staff giving out drugs are not
part of the investigation team
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results of all 161 randomised patients re-
ported for primary and secondary out-
comes
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NAFARM 2011 (Continued)
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk The study appears to be free of other
sources of bias
Ott 2003
Methods • Study design: parallel RCT
• Study duration: January and May 2000
• Study follow-up:14 POD
Participants • Countries: USA, Canada, Germany, UK
• Setting: multicentre (58)
• Inclusion criteria: patients undergoing coronary artery bypass graft surgery.
• Number: treatment group (311); control group (151)
• Mean age ± SD (years): treatment group (60.3 ± 8.2); control group (61.3 ± 8.0)
• Sex (M/F): treatment group (265/46); control group (135/16)
• Exclusion criteria: patients undergoing emergency surgery and those with a recent
(48 h) MI; insulin-dependent or uncontrolled diabetes; increased concentrations of
liver enzymes SCr > 1.5 mg/dL (or 133 µmol/L); any coagulopathy; stroke or transient
ischaemic attack within 6 months; substance abuse (opioids, any other analgesics, or
alcohol); allergy to NSAIDs; history of gastric or duodenal ulcer; intra-operative
complications
Interventions Treatment group
• Parecoxib: 40 mg IV was administered within 30 min after extubation and every
12 h for a minimum of 3 days. Subsequently, oral valdecoxib at a dose of 40 mg every
12 h was initiated and administered for a combined total of 14 days
Control group
• IV placebo: administered within 30 min after extubation and every 12 h for a
minimum of 3 days. Subsequently, oral placebo every 12 h was initiated and
administered for a combined total of 14 days
Outcomes • SCr
• Clinical adverse outcomes
Notes • A typing error was found in the presentation of results on page 1485 (an increase
in creatinine of 0.7 mg/dL is equivalent to 62 µmol/L, instead of 0.62 µmol/L as
quoted in the text).
• Note: creatinine rise as cause for withdrawal was 1.9% vs 1.3% in treatment vs
placebo group
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Ott 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk After randomisation and the administra-
tion of at least one dose of the study
drug, 26% of the 462 patients (equally dis-
tributed between groups) were withdrawn
from the study. Most frequent reason for
withdrawal was an adverse event (15.6%)
of which 1.3% in the control group and 1.
9% in the NSAID group were due to rise
in creatinine. Plausible effect size among
missing outcomes enough to induce clini-
cally relevant bias in observed effect size
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Unclear risk Insufficient information to permit judge-
ment
Perttunen 1992
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up:72 h post-operatively
Participants • Country: Finland
• Setting: single centre
• Inclusion criteria: patients undergoing thoracoscopy
• Number: treatment group (15); control group (15)
• Mean age, range (years): treatment group (59.1, 38 to 75); control group (55.3,
23 to 74)
• Sex (M/F): treatment group 1 (11/4); control group (13/2)
• Exclusion criteria: > 75 years; cardiac, kidney or hepatic failure; history of GI
bleeding or peptic ulceration; haemorrhagic diathesis and asthma; allergy to aspirin,
NSAIDs or morphine; confusion; preoperative FEV1 < 60% of reference value; sleep
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Perttunen 1992 (Continued)
apnoea
Interventions Treatment group
• Diclofenac: 400 mg in 400 mL NaCl 0.9%; 25 mL bolus given immediately after
surgery then 2 mg/kg/24 h for 48 h
Control group
• 0.9% NaCl: 400 mL; 25 mL bolus given immediately after surgery then 2 mL/kg/
24 h for 48 h
Outcomes • Pre-operative and post-operative SCr and urine output
Notes • Funding support: supported by the Paulo Foundation, Finland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study medication looks identical; double
blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nurse who made up the infusions was not
involved in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing secondary outcome data from 4/
30 patients; insufficient reporting of reason
behind missing data to permit judgement
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Non-profit organisation funding received
Perttunen 1999
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 2 POD
Participants • Country: Finland
• Setting: single centre
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Perttunen 1999 (Continued)
• 30 patients undergoing thoracoscopy
• Number: treatment group 1 (10); treatment group 2 (10); control group (10)
• Mean age, range (years): treatment group 1 (50.3, 26 to 70); treatment group 2
(40.6, 18 to 64); control group (45.0, 25 to 70)
• Sex (M/F): treatment group 1 (5/5); treatment group 2 (6/4); control group (5/5)
• Exclusion criteria: > 75 years; cardiac, kidney or hepatic failure; history of GI
bleeding or peptic ulceration; haemorrhagic diathesis and asthma; allergy to aspirin,
NSAIDs or morphine; confusion, preoperative FEV1 < 60% of reference value; sleep
apnoea
Interventions Treatment group 1
• Diclofenac: bolus of 17 mg 1 h before anaesthesia; followed by a 48 h continuous
infusion at 1mg/kg/24 h
Treatment group 2
• Diclofenac: bolus of 10 mg 1 h before anaesthesia, followed by a 48 h continuous
infusion at 1.2mg/kg/24 h
Control group
• Equivalent placebo bolus and continuous infusion
Outcomes • Creatinine at baseline, 1 h, first POD and second POD
• Urine output measurement 0-22 h and 22-46 h
Notes • Funding Source: Helsinki University Central Hospital Research Fund and
Helsinki University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Envelopes were sealed and opened by nurse
who was not involved in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Envelopes were sealed and opened by re-
covery nurse who made up the infusions.
This nurse was not involved in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to allocation of in-
fusions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
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Other bias Low risk Non-profit organisation funding received
POISE-2 2013
Methods • Study design: parallel RCT
• Study duration: January 2011 to December 2013
• Study follow-up: 30 POD
Participants • Countries: Canada, USA, Colombia, India, Spain, Australia, South Africa,
Denmark, Hong Kong, Belgium, Austria, Pakistan, Peru, Malaysia, Italy, Chile,
Switzerland, France, UK, Brazil, New Zealand
• Setting: multicentre (88)
• Inclusion criteria: patients undergoing non-cardiac surgery
• Number: treatment group 1 (3443); treatment group 2 (3453); control group 1
(3462); control group 2 (3452)
• Mean age ± SD (years): treatment group 1 (69.3 ± 9.9); treatment group 2 (69.1 ±
10.0); control group 1 (69.1 ± 10.0); control group 2 (69.2 ± 9.9)
• Sex (M/F): treatment group 1 (1808/1635);treatment group 2 (1846/1607);
control group 1 (1861/1601); control group 2 (1823/1629)
• Exclusion criteria: ESKD prior to randomisation; no pre- or post-randomisation
SCr measurement available
Interventions Treatment group 1
• Aspirin: 200 mg 2 to 4 h before surgery and then 100 mg for either 7 days (for
those taking long-term aspirin) or 30 days (for those not taking long-term aspirin)
Treatment group 2 (not included in meta-analyses)
• Oral clonidine: 0.2 mg 2 to 4 h before surgery and then a transdermal clonidine
patch (which provided clonidine 0.2 mg/d) until 72 h after surgery
Control group 1
• Placebo: 2 to 4 h before surgery and then placebo for up to 30 days after surgery
Control group 2 (not included in meta-analyses)
• Placebo: 2 to 4 h before surgery and then a transdermal placebo patch until 72 h
after surgery
Outcomes • AKI
• Dialysis within 30 days
Notes • Treatment group 2 and control group 2 not included in the meta-analyses (wrong
intervention)
• Funding source: funding received from the industry. Sponsors of the study had no
role in the design and conduct of the study, data collection and analysis or publication.
• Financial support provided from Australian National Health and Medical
Research Council, the Spanish Ministry of Health and Social Policy. Study drugs were
provided by Boehringer Ingelheim and Bayer Pharma AG. Boehringer Ingelheim
provided an uncertain amount of funding
• Up to 10% of patients included had an eGFR of 45 mL/min or less at start of the
study
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerized randomisation
Allocation concealment (selection bias) Low risk Concealed allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients, clinicians, data collectors, and
outcome adjudicators were blinded to the
allocation of each intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patients, clinicians, data collectors, and
outcome adjudicators were blinded to the
allocation of each intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 5% missing creatinine values
were reported. Multiple imputation mod-
els were used to handle missing data, which
all yielded similar results
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Contribution of funding sources unclear,
however financial support provided by two
large governmental non-profit organisa-
tions. The authors state that the sponsors
had no role in the design and conduct of
the study, collection, management, analy-
sis, review or approval of the manuscript;
and decision to submit the manuscript for
publication
Power 1992
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 2 POD
Participants • Country: UK
• Setting: single centre
• Inclusion criteria: patients undergoing open oesophagogastrectomy for cancer
• Number: treatment group 1 (10); control group (10)
• Mean age, range (years): treatment group (65.2, 51 to 76); control group (69.8,
50 to 79)
• Sex (M/F): treatment group (9/1); control group (8/2)
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Power 1992 (Continued)
• Exclusion criteria: history of peptic ulceration, asthma, previous reactions to
NSAID, allergies, evidence of kidney insufficiency, diuretic therapy and recent NSAID
ingestion.
Interventions Treatment group
• Diclofenac: 75 mg IM at induction then 4 doses (75 mg each) every 12 h for 48 h
Control group
• Placebo: at induction then 4 doses every 12 h for 48 h
Outcomes • Pre-operative and post-operative (day of the surgery, 1 day after surgery)
measurement of CrCl, SCr, urine output, sodium output, potassium output, number
of patients on diuretic or dopamine to treat post-operative kidney insufficiency
Notes • Funding source: not reported
• One patient in diclofenac group withdrawn due to low urine output and was later
found to have had a reduced preoperative CrCl (45 mL/min). This patient recovered
after IV dopamine and frusemide administration. In this study, frusemide 10 mg IV
was given if urine flow rate was < 30 mL/h for 2 consecutive periods of 1 h
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was reported as randomised; method
of randomisation not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Standardised management for intervention
and anaesthetic technique and fluid ther-
apy, however unclear how patients and per-
sonnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 out of 20 patients, randomised to the ac-
tive study drug group, was withdrawn af-
ter 18 h due to oliguria and severe AKI.
It is plausible that the effect is enough to
induce clinically relevant bias in observed
effect size
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
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Other bias Unclear risk Insufficient information to permit judge-
ment
Puolakka 2009
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 20 h post-operatively
Participants • Country: Finland
• Setting: single centre
• Inclusion criteria: patients undergoing laparoscopic hysterectomy
• Number: treatment group (15); control group (15)
• Mean age ± SD (years): treatment group (48.5 ± 7.9); control group (50.5 ± 4.5)
• Sex (M/F): All female
• Exclusion criteria: allergy to aspirin-like drugs or sulphonamide; bronchial
asthma; liver or kidney disturbances; peptic ulcer; bleeding disorder; pregnancy;
substance abuse; chronic pain
Interventions Treatment group
• Parecoxib: single dose of 80 mg IV, before the induction of anaesthesia
Control group
• Saline
Outcomes • SCr and sensitive urine and serum markers for renal tubular injury directly after
induction of anaesthesia, 2 h after induction, first and second POD
Notes • Post hoc analysis shows that study is underpowered to detect statistically
significant serious adverse events
• Funding source: supported by the Medical Research Fund of Tampere University
Hospital, Finland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Random numbers in opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Nurse not involved in the study made up
the study drugs
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients withdrawn. Missing data from
2 patients at variable time points. Missing
outcome data balanced in numbers across
intervention groups
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk Non-profit organisation funding received
Rafiq 2014
Methods • Study design: parallel RCT
• Study duration: March 2007 to August 2009
• Study follow-up: 30 POD
Participants • Country: Denmark
• Setting: single centre
• Inclusion criteria: patients requiring cardiac surgery (medial sternotomy)
• Number: treatment group (77); control group (74)
• Mean age ± SD (years): treatment group (62 ± 12); control group (64 ± 13)
• Sex (M/F): treatment group (61/16); control group (59/15)
• Exclusion criteria; peripheral neuropathy; neurological disease; psychiatric illness;
history of GI bleeding; chronic pain; SCr >150 µmol/L, hepatic disease with elevated
liver enzymes; allergic to study medication; alcohol abuse; abuse of narcotics or
medication; pregnancy; participation in other clinical trials; insufficient language skills;
ICU stay > 24 h
Interventions Treatment group
• Ketorolac: 30 mg IV during extubation, followed by ibuprofen 400 mg 4 times/d
Control group
• Morphine: 10 mg 4 times/d.
Outcomes • Maximum post-operative SCr and individual rise in SCr
• Length of hospital stay, death and need for RRT post-operatively
Notes • Funding source: no funding received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque sealed en-
velope
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 180 randomised patients, 29 patients
were withdrawn prior to administration
of the study drug. Missing outcome data
balanced in numbers across intervention
group with similar reasons for missing data
across groups
Selective reporting (reporting bias) Low risk Maximum SCr reported
Other bias Low risk The study appears to be free of other
sources of bias
Rapanos 1999
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 24 h post-operatively
Participants • Country: Canada
• Setting: single centre
• Inclusion criteria: adults undergoing elective aortocoronary bypass surgery
• Number: treatment group (31); control group (26)
• Median age ± SD (years): treatment group (62.2 ± 9.5); control group (59.4 ± 9.4)
• Sex (M/F): treatment group (25/6); control group (20/6)
• Exclusion criteria: previous history of peptic ulcer or GI bleeding; hepatic or
kidney insufficiency; insulin dependent DM; known allergy to aspirin or NSAIDs; use
of aspirin in the 5 days prior to surgery; gastro-epiploic artery conduit; weight < 60 kg;
inability to operate patient controlled analgesia device
Interventions Treatment group
• Indomethacin: 100 mg suppository 2 to 3 h after surgery and again 12 h later
Control group
• Placebo: suppository 2 to 3 h after surgery and again 12 h later
Outcomes • Pre-operative and post-operative SCr
Notes • Funding source: Technilab Inc. supplied study drugs, without any financial
support
• 125 patients were consented and enrolled in the study preoperatively. Fifty-five
patients were excluded post-operatively due to excessive blood loss. A further 10
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patients were excluded due to protocol violations
• A very healthy subgroup was studied
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation carried out by pharmacy
department
Allocation concealment (selection bias) Low risk Sequential selection of previously ran-
domised envelopes; envelopes containing
study drug or placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs and placebo suppositories in
envelopes appearing similar
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study drugs and placebo suppositories in
envelopes appearing similar
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk The study appears to be free of other
sources of bias
Slaven 1998
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 6 h
Participants • Country: New Zealand
• Setting: single centre
• Inclusion criteria: healthy as judged by medical history, physical examination,
routine biochemical and haematological screening and were rated as American Society
of Anaesthesiologists (ASA) classification undergoing elective lower back surgery
(laminectomies)
• Number: treatment group (10); control group (10)
• Mean age ± SD (years): treatment group (39.6 ± 14.1); control group (38.3 ± 7.2)
• Sex (M/F): treatment group (10/0); control group (6/4)
• Exclusion criteria: not reported
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Interventions Treatment group
• Tenoxicam: 40 mg IV prior to induction
Control group
• Placebo: IV prior to induction
Outcomes • Urinary CrCl, osmolar clearance and free water clearance
Notes • Funding source: tenoxicam-placebo gift from Roche Products New Zealand Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation performed by pharmacist,
randomisation technique unknown
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active agent and placebo drugs were de-
livered to the theatre room in prefilled sy-
ringes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Low risk The tenocixam-placebo was a gift from
Roche Products New Zealand (the manu-
facturer). The study design and analysis of
the results were independent of any phar-
maceutical company involvement
Turner 1994
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 3 POD
Participants • Country: Australia
• Setting: single centre
• Inclusion criteria: patients undergoing elective open cholecystectomy
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• Number: treatment group (24); control group (24)
• Mean age ± SD (years): treatment group (56.5 ± 16.6); control group (49.0 ± 15.
3)
• Sex (M/F): treatment group (8/16); control group (10/14)
• Exclusion criteria: history of peptic ulceration; bleeding disorder; kidney
impairment; haemorrhoids
Interventions Treatment group
• Indomethacin suppositories: 200 mg at end of surgery then 100 mg twice daily
for 3 days
Control group
• Placebo suppositories: according to same treatment regimen.
Outcomes • Pre-operative and post-operative (48 h) SCr was measured in 19/50 patients
Notes • No pre-operative and post-operative SCr measures given, rather the mean change
was given for each group
• Funding Source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Sequential selection of previously ran-
domised envelopes, study drugs appearing
identical
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients, nursing staff and medical staff
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patients, nursing staff and medical staff
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 50 patients were included in the study, 2
patientswerewithdrawndue toprotocol vi-
olation. Of the remaining 48 patients kid-
ney outcome datawas available from38pa-
tients (11% missing data). No reasons for
missing data was provided
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
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Other bias Unclear risk Insufficient information to permit judge-
ment
Varrassi 1994
Methods • Study design: parallel RCT
• Study duration: not reported
• Study follow-up: 24 h post-operatively
Participants • Country: Italy
• Setting: single centre
• Inclusion criteria: patients undergoing elective cholecystectomy
• Number: treatment group (48); control group (47)
• Mean age ± SE (years): treatment group (52.5 ± 1.4); control group (50.2 ± 1.6)
• Sex (M/F): treatment group (17/31); control group (15/32)
• Exclusion criteria: pregnancy; history of peptic ulceration; coagulopathies;
impaired kidney function; allergy or intolerance to NSAIDs; alcohol or opioid abuse;
children; > 65 years
Interventions Treatment group
• Ketorolac: 30 mg IM before surgery then 2 mg/h IV infusion for 24 h
Control group
• Normal saline: 1 mL IM then 2 mL/h IV infusion for 24 h
Outcomes • Post-operative SCr
Notes • Funding Source: supported in part by CNR Grants
• SCr level taken in recovery (and after first IM injection of ketorolac/placebo) is
used as baseline SCr level. No pre-operative SCr reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Varrassi 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 out of 100 patients were withdrawn from
the study after randomisation and adminis-
tration of the study drug. Reasons for miss-
ing outcome data unlikely to be related to
true outcome
Selective reporting (reporting bias) Low risk Study protocol matches outcomes pre-
sented
Other bias Unclear risk Insufficient information to permit judge-
ment
AKI - acute kidney injury; ASA - American Society of Anesthesiologists; CrCl - creatinine clearance; DM - diabetes mellitus; eGFR
- estimated glomerular filtration rate; ESKD - end-stage kidney disease; GI - gastrointestinal; ICU - intensive care unit; IM -
intramuscular; IV - intravenous; MI - myocardial infarction; NSAIDs - nonsteroidal anti-inflammatory drugs; POD - post-operative
day/s; RRT - renal replacement therapy; SCr - serum creatinine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Castiglione 1997 Wrong control group: control group also received ketorolac
Cheruku 2004 Wrong population: patients included with a SCr up to 2.0 mg/dL
Insufficient post-operative outcome measures reported; kidney function given for 3/100 patients only; all of
those had a SCr above 2.0 mg/dL
Chow 2001 Wrong population: one third of patients underwent a nephrectomy; patients were excluded when a significant
SCr rise was noted
Daniels 2014 Abstract-only publication; no kidney function outcome measures documented
Doyle 1998 Wrong control group: patients randomised to 2 analgesic regimens
Fredman 1999 No relevant post-operative kidney outcome measures
Grimsby 2012 Wrong population: patients with CKD were included and 111/128 patients underwent a nephrectomy
Hynes 2006 No relevant post-operative kidney outcome measures
Leeson 2007 Kidney function parameters not clearly defined
Ma 2015 No kidney function parameters documented
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(Continued)
Merry 2002 Wrong population: patients with CKD included
Nussmeier 2005 Included 6 (1%) of patients with kidney insufficiency.
Post-operative kidney failure or dysfunction reported at any time during the 30 days after surgery. No data given
for the first 2 days after surgery
Nussmeier 2006 Patients were included when kidney disease was deemed significant by the investigator; 6 patients had kidney
insufficiency (unknown eGFR) on randomisation
Adverse events were recorded. No SCr or urine output individually reported
Nuutinen 1991 No concise kidney outcome measures reported
Parker 1994 No concise kidney outcome measures reported
Rao 2000 Ambiguity regarding inclusion criteria. Patients excluded when ‘significant renal disease’ was present. No concise
kidney outcomes documented; 1 patient developed transient kidney failure
Ready 1994 No concise kidney outcome measures reported
Southworth 2009 No concise kidney outcome measures reported
Varrassi 1999 No concise kidney outcomes measures reported; comment made that there was not statistically significant
difference between treatment groups
CKD - chronic kidney disease; CrCl - creatinine clearance; eGFR - estimated glomerular filtration rate; SCr - serum creatinine
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D A T A A N D A N A L Y S E S
Comparison 1. Acute kidney injury
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AKI 2 7066 Risk Ratio (M-H, Random, 95% CI) 1.79 [0.40, 7.96]
Comparison 2. Serum creatinine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serum creatinine (all studies) 15 794 Mean Difference (IV, Random, 95% CI) 3.23 [-0.80, 7.26]
2 Serum creatinine (excluding
high risk of bias)
7 429 Mean Difference (IV, Random, 95% CI) 2.64 [-1.28, 6.55]
3 Serum creatinine (excluding
high attrition bias)
11 601 Mean Difference (IV, Random, 95% CI) 2.96 [-1.57, 7.49]
4 Serum creatinine (excluding high
risk of bias or high attrition
bias)
6 331 Mean Difference (IV, Random, 95% CI) 3.57 [-1.35, 8.48]
Comparison 3. Urine output
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Urine output 6 149 Std. Mean Difference (IV, Random, 95% CI) -0.49 [-1.21, 0.24]
Comparison 4. Need for renal replacement therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 RRT 2 7056 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.49, 5.07]
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Comparison 5. Death due to any cause
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death due to any cause 2 312 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.19, 11.12]
Comparison 6. Length of hospital stay
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Length of hospital stay 3 410 Mean Difference (IV, Random, 95% CI) 0.12 [-0.48, 0.72]
Analysis 1.1. Comparison 1 Acute kidney injury, Outcome 1 AKI.
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 1 Acute kidney injury
Outcome: 1 AKI
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
NAFARM 2011 6/82 1/79 29.6 % 5.78 [ 0.71, 46.94 ]
POISE-2 2013 462/3443 426/3462 70.4 % 1.09 [ 0.96, 1.23 ]
Total (95% CI) 3525 3541 100.0 % 1.79 [ 0.40, 7.96 ]
Total events: 468 (NSAID), 427 (Placebo)
Heterogeneity: Tau2 = 0.82; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with NSAID Less with placebo
60Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Serum creatinine, Outcome 1 Serum creatinine (all studies).
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 2 Serum creatinine
Outcome: 1 Serum creatinine (all studies)
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Power 1992 9 15 (42.37) 9 17 (35.64) 1.1 % -2.00 [ -38.17, 34.17 ]
Rafiq 2014 77 34.4 (54.43) 74 19.6 (44.8) 4.1 % 14.80 [ -1.07, 30.67 ]
Varrassi 1994 48 13.26 (47.25) 47 12.38 (27.78) 4.2 % 0.88 [ -14.67, 16.43 ]
Perttunen 1999 10 -1 (18.62) 10 -17 (12.35) 4.9 % 16.00 [ 2.15, 29.85 ]
Kostamovaara 1996 18 -8 (20.07) 19 -19 (19.31) 5.4 % 11.00 [ -1.70, 23.70 ]
Perttunen 1992 12 -4 (13.86) 14 -4 (18.67) 5.5 % 0.0 [ -12.54, 12.54 ]
Fayaz 2004 17 7 (13.89) 20 10 (19.31) 6.4 % -3.00 [ -13.73, 7.73 ]
Turner 1994 24 -1.53 (14.45) 24 0.26 (17.42) 7.3 % -1.79 [ -10.84, 7.26 ]
Eljezi 2017 24 -13.5 (14.05) 25 -7.38 (14.64) 7.9 % -6.12 [ -14.15, 1.91 ]
Rapanos 1999 31 -15.9 (15.81) 26 -17 (14.28) 8.1 % 1.10 [ -6.72, 8.92 ]
Puolakka 2009 14 2 (9.69) 15 -1 (10.18) 8.4 % 3.00 [ -4.23, 10.23 ]
Hynninen 2000 28 1 (11.14) 31 -10 (16) 8.6 % 11.00 [ 4.02, 17.98 ]
Kulik 2004 50 -7.6 (16.97) 48 -8 (15.24) 9.0 % 0.40 [ -5.98, 6.78 ]
Laisalmi 2001a 15 -6.2 (8.84) 15 -0.9 (8.84) 9.0 % -5.30 [ -11.63, 1.03 ]
Immer 2003 20 9 (8.23) 20 -2.8 (6.35) 10.1 % 11.80 [ 7.24, 16.36 ]
Total (95% CI) 397 397 100.0 % 3.23 [ -0.80, 7.26 ]
Heterogeneity: Tau2 = 36.45; Chi2 = 40.98, df = 14 (P = 0.00018); I2 =66%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Lower with NSAID Lower with placebo
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Analysis 2.2. Comparison 2 Serum creatinine, Outcome 2 Serum creatinine (excluding high risk of bias).
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 2 Serum creatinine
Outcome: 2 Serum creatinine (excluding high risk of bias)
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Rafiq 2014 77 34.4 (54.43) 74 19.6 (44.8) 5.6 % 14.80 [ -1.07, 30.67 ]
Perttunen 1999 10 -1 (18.62) 10 -17 (12.35) 7.2 % 16.00 [ 2.15, 29.85 ]
Perttunen 1992 12 -4 (13.86) 14 -4 (18.67) 8.6 % 0.0 [ -12.54, 12.54 ]
Turner 1994 24 -1.53 (14.45) 24 0.26 (17.42) 14.8 % -1.79 [ -10.84, 7.26 ]
Rapanos 1999 31 -15.9 (15.81) 26 -17 (14.28) 18.5 % 1.10 [ -6.72, 8.92 ]
Puolakka 2009 14 2 (9.69) 15 -1 (10.18) 20.7 % 3.00 [ -4.23, 10.23 ]
Kulik 2004 50 -7.6 (16.97) 48 -8 (15.24) 24.6 % 0.40 [ -5.98, 6.78 ]
Total (95% CI) 218 211 100.0 % 2.64 [ -1.28, 6.55 ]
Heterogeneity: Tau2 = 5.57; Chi2 = 7.52, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Lower with NSAID Lower with placebo
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Analysis 2.3. Comparison 2 Serum creatinine, Outcome 3 Serum creatinine (excluding high attrition bias).
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 2 Serum creatinine
Outcome: 3 Serum creatinine (excluding high attrition bias)
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Rafiq 2014 77 34.4 (54.43) 74 19.6 (44.8) 5.5 % 14.80 [ -1.07, 30.67 ]
Varrassi 1994 48 13.26 (47.25) 47 12.38 (27.78) 5.6 % 0.88 [ -14.67, 16.43 ]
Perttunen 1999 10 -1 (18.62) 10 -17 (12.35) 6.5 % 16.00 [ 2.15, 29.85 ]
Kostamovaara 1996 18 -8 (20.07) 19 -19 (19.31) 7.2 % 11.00 [ -1.70, 23.70 ]
Perttunen 1992 12 -4 (13.86) 14 -4 (18.67) 7.3 % 0.0 [ -12.54, 12.54 ]
Turner 1994 24 -1.53 (14.45) 24 0.26 (17.42) 10.0 % -1.79 [ -10.84, 7.26 ]
Eljezi 2017 24 -13.5 (14.05) 25 -7.38 (14.64) 10.9 % -6.12 [ -14.15, 1.91 ]
Rapanos 1999 31 -15.9 (15.81) 26 -17 (14.28) 11.1 % 1.10 [ -6.72, 8.92 ]
Puolakka 2009 14 2 (9.69) 15 -1 (10.18) 11.6 % 3.00 [ -4.23, 10.23 ]
Hynninen 2000 28 1 (11.14) 31 -10 (16) 11.9 % 11.00 [ 4.02, 17.98 ]
Laisalmi 2001a 15 -6.2 (8.84) 15 -0.9 (8.84) 12.5 % -5.30 [ -11.63, 1.03 ]
Total (95% CI) 301 300 100.0 % 2.96 [ -1.57, 7.49 ]
Heterogeneity: Tau2 = 32.36; Chi2 = 24.69, df = 10 (P = 0.01); I2 =59%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Lower with NSAID Lower with placebo
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Analysis 2.4. Comparison 2 Serum creatinine, Outcome 4 Serum creatinine (excluding high risk of bias or
high attrition bias).
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 2 Serum creatinine
Outcome: 4 Serum creatinine (excluding high risk of bias or high attrition bias)
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Rafiq 2014 77 34.4 (54.43) 74 19.6 (44.8) 8.2 % 14.80 [ -1.07, 30.67 ]
Perttunen 1999 10 -1 (18.62) 10 -17 (12.35) 10.4 % 16.00 [ 2.15, 29.85 ]
Perttunen 1992 12 -4 (13.86) 14 -4 (18.67) 12.2 % 0.0 [ -12.54, 12.54 ]
Turner 1994 24 -1.53 (14.45) 24 0.26 (17.42) 19.6 % -1.79 [ -10.84, 7.26 ]
Rapanos 1999 31 -15.9 (15.81) 26 -17 (14.28) 23.7 % 1.10 [ -6.72, 8.92 ]
Puolakka 2009 14 2 (9.69) 15 -1 (10.18) 25.9 % 3.00 [ -4.23, 10.23 ]
Total (95% CI) 168 163 100.0 % 3.57 [ -1.35, 8.48 ]
Heterogeneity: Tau2 = 10.65; Chi2 = 7.03, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Lower with NSAID Lower with placebo
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Analysis 3.1. Comparison 3 Urine output, Outcome 1 Urine output.
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 3 Urine output
Outcome: 1 Urine output
Study or subgroup NSAID Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Power 1992 9 0.62 (0.06) 9 0.88 (0.13) 13.0 % -2.45 [ -3.74, -1.15 ]
Irwin 1995 11 -0.23 (0.34) 10 0.32 (0.49) 16.0 % -1.26 [ -2.22, -0.31 ]
Perttunen 1999 10 992 (653.29) 10 1452 (710.4) 16.5 % -0.65 [ -1.55, 0.26 ]
Perttunen 1992 15 1179 (347.94) 15 1038 (435.37) 18.1 % 0.35 [ -0.37, 1.07 ]
Laisalmi 2001a 15 0.6 (3.76) 15 -0.8 (6.34) 18.2 % 0.26 [ -0.46, 0.98 ]
Jones 2000 15 1870 (2678.5) 15 1520 (1036) 18.2 % 0.17 [ -0.55, 0.88 ]
Total (95% CI) 75 74 100.0 % -0.49 [ -1.21, 0.24 ]
Heterogeneity: Tau2 = 0.63; Chi2 = 22.02, df = 5 (P = 0.00052); I2 =77%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Lower with NSAID Lower with placebo
65Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Need for renal replacement therapy, Outcome 1 RRT.
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 4 Need for renal replacement therapy
Outcome: 1 RRT
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rafiq 2014 1/77 2/74 20.3 % 0.48 [ 0.04, 5.19 ]
POISE-2 2013 19/3443 9/3462 79.7 % 2.12 [ 0.96, 4.69 ]
Total (95% CI) 3520 3536 100.0 % 1.57 [ 0.49, 5.07 ]
Total events: 20 (NSAID), 11 (Placebo)
Heterogeneity: Tau2 = 0.29; Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with NSAID Less with placebo
Analysis 5.1. Comparison 5 Death due to any cause, Outcome 1 Death due to any cause.
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 5 Death due to any cause
Outcome: 1 Death due to any cause
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rafiq 2014 1/77 2/74 47.1 % 0.48 [ 0.04, 5.19 ]
NAFARM 2011 4/82 1/79 52.9 % 3.85 [ 0.44, 33.73 ]
Total (95% CI) 159 153 100.0 % 1.44 [ 0.19, 11.12 ]
Total events: 5 (NSAID), 3 (Placebo)
Heterogeneity: Tau2 = 0.83; Chi2 = 1.61, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with NSAID Less with placebo
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Analysis 6.1. Comparison 6 Length of hospital stay, Outcome 1 Length of hospital stay.
Review: Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
Comparison: 6 Length of hospital stay
Outcome: 1 Length of hospital stay
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Random,95% CI IV,Random,95% CI
NAFARM 2011 82 18.33 (9.59) 79 17.23 (7.39) 4.9 % 1.10 [ -1.54, 3.74 ]
Rafiq 2014 77 8.2 (4.6) 74 7.4 (3.3) 17.7 % 0.80 [ -0.47, 2.07 ]
Kulik 2004 50 5.3 (0.2) 48 5.4 (0.7) 77.4 % -0.10 [ -0.31, 0.11 ]
Total (95% CI) 209 201 100.0 % 0.12 [ -0.48, 0.72 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Lower with NSAID Lower with placebo
A D D I T I O N A L T A B L E S
Table 1. Effect modifiers for meta-regression of change in post-operative serum creatinine
Study ID Cardiac surgery NSAIDs > 24 hours Age exclusion
Eljezi 2017 Yes Yes > 75 years
Fayaz 2004 Yes No None reported
Hynninen 2000 Yes No > 75 years
Immer 2003 Yes Yes, 3 days > 70 years
Kostamovaara 1996 No, hip or knee replacement No None reported
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Table 1. Effect modifiers for meta-regression of change in post-operative serum creatinine (Continued)
Kulik 2004 Yes Yes, 5 days None reported
Laisalmi 2001a No, breast surgery No None reported
Perttunen 1992 No, thoracoscopy Yes, 2 days > 75 years
Perttunen 1999 No, thoracoscopy Yes, 2 days > 75 years
Power 1992 No, oesophagogastrectomy Yes, 2 days None reported
Puolakka 2009 No, laparoscopic hysterectomy No None reported
Rafiq 2014 Yes Yes, 4 days None reported
Rapanos 1999 Yes No None reported
Turner 1994 No, cholecystectomy Yes, 3 days None reported
Varrassi 1994 No, cholecystectomy No > 65 years
NSAIDs - nonsteroidal anti-inflammatory drugs
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
2. ((non-steroidal next anti-inflammatory) next (agent* or drug*)):ti,ab,kw
3. ((nonsteroidal next anti-inflammatory) next (agent* or drug*)):ti,ab,kw
4. ((non-steroidal next antiinflammatory) next (agent* or drug*)):ti,ab,kw
5. ((nonsteroidal next antiinflammatory) next (agent* or drug*)):ti,ab,kw
6. NSAID*:ti,ab,kw
7. ((cox 2 inhibitor*) or (cox-2 inhibitor*)):ti,ab,kw
8. (cyclooxygenase near/2 Inhibitor*):ti,ab,kw
9. apazone:ti,ab,kw
10. aspirin:ti,ab,kw
11. clonixin:ti,ab,kw
12. diclofenac:ti,ab,kw
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(Continued)
13. diflunisal:ti,ab,kw
14. epirizole:ti,ab,kw
15. fenoprofen:ti,ab,kw
16. feprazone:ti,ab,kw
17. flurbiprofen:ti,ab,kw
18. ibuprofen:ti,ab,kw
19. indomethacin:ti,ab,kw
20. ketoprofen:ti,ab,kw
21. ketorolac:ti,ab,kw
22. meclofenamic acid:ti,ab,kw
23. mefenamic acid:ti,ab,kw
24. naproxen:ti,ab,kw
25. niflumic acid:ti,ab,kw
26. phenylbutazone:ti,ab,kw
27. piroxicam:ti,ab,kw
28. salicylates:ti,ab,kw
29. sulindac:ti,ab,kw
30. tolmetin:ti,ab,kw
31. celecoxib:ti,ab,kw
32. etodolac:ti,ab,kw
33. meloxicam:ti,ab,kw
34. parecoxib:ti,ab,kw
35. rofecoxib:ti,ab,kw
36. tenoxicam:ti,ab,kw
37. valdecoxib:ti,ab,kw
38. {or #1-#37}
39. analgesi*:ti,ab,kw
40. an*esthesia:ti,ab,kw
41. pain:ti,ab,kw
42. (peri-operativ* or perioperativ*):ti,ab,kw
43. (postoperativ* or post-operativ*):ti,ab,kw
44. (preoperativ* or pre-operativ*):ti,ab,kw
45. {or #39-#44}
46. kidney:ti,ab,kw
47. renal:ti,ab,kw
48. creatinine:ti,ab,kw
49. nephrotoxi*:ti,ab,kw
50. azot*emia:ti,ab,kw
51. dialysis:ti,ab,kw
52. (hemodia* or haemodia* or hemofiltr* or haemofiltr*):ti,ab,kw
53. (“glomerular filtration rate” or “glomerulus filtration rate”):ti,ab,kw
54. (gfr or egfr):ti,ab,kw
55. (urin* near/2 (volume or output)):ti,ab,kw
56. {or #46-#55}
57. {and #38, #45, #56}
58. MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees and with qualifier(s): [Adverse
effects - AE]
59. {and #45, #58}
60. {or #57, #59}
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(Continued)
MEDLINE 1. exp Anti-Inflammatory Agents, Non-Steroidal/
2. (non-steroidal anti-inflammatory adj (agent* or drug*)).tw.
3. (nonsteroidal anti-inflammatory adj (agent* or drug*)).tw.
4. (non-steroidal antiinflammatory adj (agent* or drug*)).tw.
5. (nonsteroidal antiinflammatory adj (agent* or drug*)).tw.
6. NSAID*.tw.
7. cox 2 inhibitor*.tw.
8. (cyclooxygenase adj2 Inhibitor*).tw.
9. apazone.tw.
10. aspirin.tw.
11. clonixin.tw.
12. diclofenac.tw.
13. diflunisal.tw.
14. epirizole.tw.
15. fenoprofen.tw.
16. feprazone.tw.
17. flurbiprofen.tw.
18. ibuprofen.tw.
19. indomethacin.tw.
20. ketoprofen.tw.
21. ketorolac.tw.
22. meclofenamic acid.tw.
23. mefenamic acid.tw.
24. naproxen.tw.
25. niflumic acid.tw.
26. phenylbutazone.tw.
27. piroxicam.tw.
28. salicylates.tw.
29. sulindac.tw.
30. tolmetin.tw.
31. celecoxib.tw.
32. etodolac.tw.
33. tenoxicam.tw.
34. parecoxib.tw.
35. rofecoxib.tw.
36. meloxicam.tw.
37. valdecoxib.tw.
38. or/1-37
39. exp Analgesia/
40. analgesi*.tw.
41. an?esthesia.tw.
42. Pain/
43. Acute Pain/
44. Pain, Postoperative/
45. Pain Management/
46. Perioperative Period/
47. Postoperative Period/
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(Continued)
48. (peri-operative or perioperative).tw.
49. (postoperative or post-operative).tw.
50. Preoperative Period/
51. (preoperative or pre-operative).tw.
52. Postoperative Complications/
53. pain.tw.
54. or/39-53
55. and/38,54
56. Kidney/
57. Kidney Diseases/
58. Renal Insufficiency/
59. exp Acute Kidney Injury/
60. Creatinine/
61. Kidney Function Tests/
62. (kidney* or renal).tw.
63. creatinine.tw.
64. (nephrotox*).tw.
65. azot?emia.tw.
66. Renal Replacement Therapy/
67. exp Renal Dialysis/
68. dialysis.tw.
69. (hemodia* or haemodia* or hemofiltr* or haemofiltr*).tw.
70. glomerular filtration rate.tw.
71. (gfr or egfr).tw.
72. (urin* adj2 (volume or output)).tw.
73. or/56-72
74. and/55,73
75. exp Anti-Inflammatory Agents, Non-Steroidal/ae
76. and/54,75
77. or/74,76
EMBASE 1. exp nonsteroid antiinflammatory agent/
2. (non-steroidal anti-inflammatory adj (agent* or drug*)).tw.
3. (nonsteroidal anti-inflammatory adj (agent* or drug*)).tw.
4. (non-steroidal antiinflammatory adj (agent* or drug*)).tw.
5. (nonsteroidal antiinflammatory adj (agent* or drug*)).tw.
6. NSAID*.tw.
7. exp Cyclooxygenase 2 Inhibitor/
8. cox 2 inhibitor*.tw.
9. (cyclooxygenase adj2 Inhibitor*).tw.
10. apazone.tw.
11. aspirin.tw.
12. clonixin.tw.
13. diclofenac.tw.
14. diflunisal.tw.
15. epirizole.tw.
16. fenoprofen.tw.
17. feprazone.tw.
18. flurbiprofen.tw.
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19. ibuprofen.tw.
20. indomethacin.tw.
21. ketoprofen.tw.
22. ketorolac.tw.
23. meclofenamic acid.tw.
24. mefenamic acid.tw.
25. naproxen.tw.
26. niflumic acid.tw.
27. phenylbutazone.tw.
28. piroxicam.tw.
29. salicylates.tw.
30. sulindac.tw.
31. tolmetin.tw.
32. celecoxib.tw.
33. etodolac.tw.
34. tenoxicam.tw.
35. parecoxib.tw.
36. rofecoxib.tw.
37. meloxicam.tw.
38. valdecoxib.tw.
39. or/1-38
40. exp Analgesia/
41. analgesi*.tw.
42. an?esthesia.tw.
43. Pain/
44. Postoperative Pain/
45. Postoperative Period/
46. Postoperative Analgesia/
47. Perioperative Period/
48. Preoperative Period/
49. Postoperative Complication/
50. (postoperative or post-operative).tw.
51. (peri-operative or perioperative).tw.
52. (preoperative or pre-operative).tw.
53. pain.tw.
54. or/40-53
55. and/39,54
56. Kidney/
57. Kidney Disease/
58. Kidney Failure/
59. Acute Kidney Failure/
60. Creatinine/
61. Kidney Function/
62. Kidney Function Test/
63. (kidney or renal).tw.
64. creatinine.tw.
65. (nephrotox*).tw.
66. azot?emia.tw.
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67. exp Renal Replacement Therapy/
68. dialysis.tw.
69. (hemodia* or haemodia* or hemofiltr* or haemofiltr*).tw.
70. Glomerulus Filtration Rate/
71. glomerular filtration rate.tw.
72. (gfr or egfr).tw.
73. Urine Volume/
74. ((urin* adj2 volume) or output).tw.
75. or/56-74
76. and/55,75
77. exp nonsteroid antiinflammatory agent/ae
78. and/54,77
79. or/76,78
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
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procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
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observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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Appendix 3. Decisions based on five GRADE criteria about certainty of evidence from RCTs in
Summary of Findings Table
Outcome: post-operative acute kidney injury
Criterion Evidence Decision
Risk of bias NAFARM 2011 had unclear selection bias but the
POISE-2 2013 was at low risk of bias
Not serious
Imprecision 7066 participants and 897 events Serious: POISE-2 2013 had few events while NAFARM
2011 was stopped early
Inconsistency Chi2 = 2.43, df = 1 (P = 0.12); I2 = 59% Serious: the risk of AKI in the control groups was com-
pletely different: 1.2% in NAFARM 2011 versus 12.3%
in POISE-2 2013
Indirectness The indications for NSAID were prevention of AKI (
POISE-2 2013) or atrial fibrillation (NAFARM 2011)
rather than analgesia
Serious because the doses for these indications were
lower than the doses that would be used for analgesia in
routine care
Publication bias Large studies, not commercially sponsored other than
supply of intervention drugs and placebo
Not serious
Outcome: difference in increase in post-operative serum creatinine
Criterion Evidence Decision
Risk of bias Eight studies had high risk of bias overall or high risk of
attrition bias
Not serious: the mean difference in SCr was higher in
the six studies with low or unclear risk of bias (3.45, 0.
12 to 6.78) than in all 15 studies (3.23, -0.80 to 7.26)
Imprecision 794 participants Not serious
Inconsistency Chi2 = 40.98, df = 14 (P = 0.0002); I2 = 66% Serious: the inconsistency was not adequately explained
by pre-specified effect modifiers (Table 1)
Indirectness All of the studies hadmultiple exclusion criteria, includ-
ing age in 6 (Table 1)
Serious: the patients in these RCTs are likely to be differ-
ent from those in routine care. The results of Kulik 2004
(decrease in SCr associated with naproxen for 5 days af-
ter cardiac surgery) are in stark contrast to the results of
NAFARM 2011 (trial stopped because of excess risk of
acute kidney injury associated a lower dose of naproxen
for 5 days after cardiac surgery)
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Publication bias None of the studies were commercially sponsored Not serious
Outcome: renal replacement therapy
Criterion Evidence Decision
Risk of bias Rafiq 2014was at high risk of performance anddetection
bias
Serious
Imprecision 7056 participants, 31 events Serious, few events
Inconsistency Chi2 = 1.35, df = 1 (P = 0.25); I2 = 26% Serious: the risk of RRT in the control groups was com-
pletely different: 0.3% in NAFARM 2011 versus 2.7%
in Rafiq 2014
Indirectness The indications for NSAID was prevention of atrial fib-
rillation in the largest study (NAFARM 2011) rather
than analgesia
Serious because the dose of naproxen inNAFARM2011
was much lower than would be used for analgesia
Publication bias None of the studies were commercially sponsored Not serious
Outcome: death
Criterion Evidence Decision
Risk of bias Rafiq 2014was at high risk of performance anddetection
bias
Serious
Imprecision 312 participants, 8 events Serious: few events
Inconsistency Chi2 = 1.61, df = 1 (P = 0.20); I2 = 39% Serious: the relative risk of death was in opposite direc-
tions: 3.85 inNAFARM2011 versus 0.48 in Rafiq 2014
Indirectness The indications for NSAID was prevention of atrial fib-
rillation in the largest study (NAFARM 2011) rather
than analgesia
Serious: the dose of naproxen in NAFARM 2011 was
much lower than would be used for analgesia
Publication bias None of the studies were commercially sponsored Not serious
Outcome: length of hospital stay
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Criterion Evidence Decision
Risk of bias Rafiq 2014was at high risk of performance anddetection
bias; Kulik 2004 was at high risk of attrition bias
Serious
Imprecision 410 participants Not serious: length of stay measured in all participants
Inconsistency Chi2 = 2.63, df = 1 (P = 0.27); I2 = 24% Serious: mean length of stay in control groups varied
from 5.4 (Kulik 2004) to 17.2 days (NAFARM 2011)
Indirectness The indications for NSAID was prevention of atrial fib-
rillation in the largest study (NAFARM 2011) rather
than analgesia
Serious: the dose of naproxen in NAFARM 2011 was
much lower than would be used for analgesia
Publication bias None of the studies were commercially sponsored Not serious
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not perform a search for observational studies as outlined in the protocol as we found sufficient RCTs to address the aim of
the review. We included two studies that had an objective other than pain relief in this review. NAFARM 2011 studied the effects of
naproxen on prevention of atrial fibrillation after coronary artery bypass grafting and the POISE-2 2013 studied adverse effects of low
dose aspirin following non-cardiac surgery.
79Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
